



Peter Greenberg

Professor of Medicine (Hematology), Emeritus

Medicine - Hematology

 Curriculum Vitae available Online

CLINICAL OFFICE (PRIMARY)

- **Hematology Clinic**

875 Blake Wilbur Dr Clinic F

MC 6555

Stanford, CA 94305

Tel (650) 498-6000 **Fax** (650) 498-5030

Bio

BIO

As Director of the Stanford MDS Center, Dr Greenberg has an active clinical practice focusing on myelodysplastic syndromes (MDS) and clonal myeloid disorders. His clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for MDS patients not responding to standard therapies. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the impact of molecular mutations for a risk-based prognostic system, the IPSS-Molecular (IPSS-M). He is Chair of the NCCN Practice Guidelines Panel for MDS. His prior laboratory investigations included biologic studies of MDS-related myeloid progenitor cell proliferation as well as mutational and transcriptomic evaluation of gene expression profiles contributing to prognosis in MDS. His current investigations include evaluation of the impact of molecular taxonomic features and polymorphisms of myeloid neoplasms on treatment response and clinical outcomes.

CLINICAL FOCUS

- Cancer > Hematology
- Hematology
- Myelodysplastic Syndromes

ACADEMIC APPOINTMENTS

- Professor Emeritus, Medicine - Hematology
- Member, Bio-X
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Acting Chief, Medical Service, VA Palo Alto Health Care System, (1978-1979)
- Head, Hematology Section, VA Palo Alto Health Care System, (1979-2005)
- Chair, National Comprehensive Cancer Network Myelodysplastic Syndromes Practice Guidelines Panel, (1997-2023)

- Director, Stanford MDS Center, (1998-2023)
- Coordinator, International Working Group for Prognosis in MDS, (2009-2023)
- Member, Stanford Scientific Review Committee, (2009-2023)

HONORS AND AWARDS

- Lifetime Achievement Award for MDS, MDS Foundation (2025)
- Lifetime Achievement Award for MDS, International Workshop for MDS (2022)
- International Prize for outstanding research in myelodysplastic syndromes (MDS), J.P. McCarthy Foundation (1997)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American Society of Hematology (1972 - present)
- Member, Eastern Cooperative Oncology Group, Leukemia Committee (1993 - 2018)
- Chairman, NCCN Myelodysplastic Syndrome Guidelines Panel (1997 - present)
- Coordinator, International Working Group for Prognosis in MDS (IWG-PM) (2009 - present)
- Executive Committee, MDS Foundation, Inc (2009 - present)
- Member, World Health Organization Clinical Advisory Committee for Myeloid Malignancies (2014 - present)

PROFESSIONAL EDUCATION

- Fellowship: Stanford University Hematology and Oncology Fellowship (1971) CA
- Residency: Stanford University Internal Medicine Residency (1968) CA
- Residency: Barnes and Allied Hospitals/Washington University School of Med (1965) MO
- Internship: Barnes and Allied Hospitals/Washington University School of Med (1964) MO
- Medical Education: George Washington University School of Medicine and Health Sciences (1963) DC
- Board Certification: Hematology, American Board of Internal Medicine (1976)
- Board Certification: Internal Medicine, American Board of Internal Medicine (1970)
- B.A., Johns Hopkins University , Biological Sciences (1959)
- M.D., George Washington U Med School , Medicine (1963)

COMMUNITY AND INTERNATIONAL WORK

- Chair, ASH Committee on International Outreach, 1998-2001

LINKS

- <http://hematology.stanford.edu/>: <http://hematology.stanford.edu/>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Dr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.

CLINICAL TRIALS

- (QUANTUM-WILD) (QUIZARTINIB OR PLACEBO PLUS CHEMOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH FLT3-ITD N, Recruiting
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia, Not Recruiting
- Bevacizumab in Treating Patients With Myelodysplastic Syndrome, Not Recruiting
- Biologic Correlates for "Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy/Intermed-2/High Risk", Not Recruiting
- Biologically Focused Therapy of Treatment-Refractory MDS Patients, Not Recruiting
- DARBEPOETIN ALFA in MDS , Not Recruiting
- Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents, Not Recruiting
- Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk, Not Recruiting
- Long Term Dosing of Romiplostim in Thrombocytopenic Subjects with Myelodysplastic Syndromes, Not Recruiting
- Phase 1b Open Label Dose Optimization & Expansion of DFV890 in Adult Patients w/ Myeloid Diseases, Not Recruiting
- Phase I Splicing Modulator H3B-8800 in MDS, AML, and CML, Not Recruiting
- Phase I/II Anti-EphA3 Monoclonal Antibody KB004 in EphA3-Expressing Hematologic Malignancies, Not Recruiting
- Phase I/II Eltrombopag in Thrombocytopenic Subjects with Advanced MDS or Secondary AML after MDS, Not Recruiting
- Phase I/II R115777 in Patients with Myeloproliferative Disorders, Not Recruiting
- Phase Ib Atezolizumab (MPD3280A, Anti-PD-L1 Antibody) +/- Azacitidine in Myelodysplastic Syndromes, Not Recruiting
- Phase II Azacitidine +/- Birinapant in Higher Risk MDS / CML, Not Recruiting
- Phase II Azacitidine +/- Lenalidomide or Vorinostat in Higher-Risk MDS or CMML, Not Recruiting
- Phase II Eltrombopag in Thrombocytopenic w/ Myelodysplastic Syndromes or Acute Myeloid Leukemia, Not Recruiting
- Phase II ON 01910.Na for Intermediate1-2, or High Risk Trisomy 8 MDS, Not Recruiting
- Phase II Rigosertib in MDS, Not Recruiting
- Phase II Study of GX15-070MS for previously untreated MDS w/Anemia and/or Thrombocytopenia , Not Recruiting
- Phase III APR-246 + Azacitidine vs Azacitidine Alone in TP53 Mutant Myelodysplastic Syndromes, Not Recruiting
- Phase III Comparing MER to Tx with Lenalidomide +/- Epoetin Alfa for Low/Intermed Risk MDS, Not Recruiting
- Phase III Deferasirox (Exjade) in MDS (low/int-1 risk) and Transfusional Iron Overload (TELESTO), Not Recruiting
- Phase III Luspatercept (ACE-536) vs Placebo in Anemia Due to IPSS-R Very Low /Low /Intrmdt Risk MDS , Not Recruiting
- Phase III Magrolimab in Combo w/ Azacitidine vs Azacitidine +Placebo in Treatment-Naive HighRisk MDS, Not Recruiting
- Phase III ON 01910.Na in MDS with Excess Blasts after Relapsed/Refractory/Intolerant to 5-AZC or DAC, Not Recruiting
- Phase III Roxadustat (FG-4592) in Tx of Anemia in Low Risk MDS w/ Low RBC Transfusion Burden, Not Recruiting
- Phase IIIB Rigosertib IV in Myelodysplastic Syndrome with Excess Blasts, Not Recruiting
- Phase IIIB Rollover Evaluation of Long-Term Safety in Participants in other Luspatercept(ACE-536) CT, Not Recruiting
- Study Comparing DACOGEN® for Injection and VIDAZA® for Injection In Subjects with MDS, Not Recruiting
- Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-risk and INT-1 MDS Patients, Not Recruiting
- Survival Data Collection In Subjects Previously Enrolled In Celgene PROT CC-5013-MDS-0003, Not Recruiting
- Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders, Not Recruiting

Publications

PUBLICATIONS

- **Morphologic findings and mutational profiles of myelodysplastic neoplasms with normal versus abnormal karyotype.** *Journal of hematopathology*
Kumar, J., Jensen, A., Lu, R., Khanna, V., Stehr, H., Spinner, M., Fernandez-Pol, S., Greenberg, P. L., Tan, B.
2026; 19 (1)
- **Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.** *Blood*
Sekrecki, M., Sekrecka, A., Lattupally, R. R., Le, K., Jin, X., Mozes, C., Dwyer, B. G., Zhuang, Z., Romero, B. A., Pineda, J. M., Cao, X., Nguyen, L., Chen, et al
2026
- **A first-in-human study of stx-0712, a CCR2+cytotoxicity targeting chimera (CyTAC™) in patients with chronic leukemia (CMML) and Acute Leukemia (AML)**
Montalban-Bravo, G., DiNardo, C., Greenberg, P., Stone, R., Padron, E., Sallman, D., Lachowicz, C., Abbas, J., Mangaonkar, A., Patnaik, M., Timothy, M., Martinez, A., Morawa, et al
ELSEVIER.2025: 3874-3875
- **TCLIA polymorphism predicts AML progression in myeloid neoplasms**
Molina, A., Jensen, A., Gopakumar, J., Khanna, V., Stehr, H., Jaiswal, S., Greenberg, P.
ELSEVIER.2025: 3854-3855
- **Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts**
Getz, T., Pugh, K., Brunner, A., Bewersdorf, J., Dezern, A., Kewan, T., Borate, U., Platzbecker, U., Sekeres, M., Wei, A., Kordasti, S., Buckstein, R., Roboz, et al
ELSEVIER.2025: 3852-3854
- **A COMPARISON OF PROGNOSTIC VARIABLES AND CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED AND 4738 WITH PRIMARY MDS INCLUDING THE INFLUENCE OF TREATMENT IN MDS-PHASE**
Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R., Sekeres, M., Della Porta, M., Malcovati, L., van de Loosdrecht, A., Dezern, A., Roboz, G., Blum, S., Valent, et al
PERGAMON-ELSEVIER SCIENCE LTD.2025
- **Molecular taxonomy of MDS/CMML patients influences responses to hypomethylating agents and clinical outcomes.** *Leukemia research*
Molina, A., Khanna, V., Jensen, A., Stehr, H., Tan, B., Yatsenko, S., Greenberg, P. L.
2025; 156: 107736
- **Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.** *Blood*
Borate, U., Pugh, K., Waller, A., Welkie, R. L., Huang, Y., Bewersdorf, J. P., Stahl, M., DeZern, A. E., Platzbecker, U., Sekeres, M. A., Wei, A. H., Buckstein, R. J., Roboz, et al
2025; 145 (13): 1369-1381
- **NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Greenberg, P. L., Stone, R. M., Abaza, Y., Al-Kali, A., Anand, S., Ball, B., Bennett, J. M., Borate, U., Brunner, A. M., Chai-Ho, W., Curtin, P., DeZern, A. E., Gaensler, et al
2025; 23 (3): 66-75
- **Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DfV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study**
Garcia-Manero, G., Abaza, Y., Greenberg, P. L., Haque, T., Kennedy, K., Della Porta, M., Ooi, M. G., Stahl, M., Xie, Z., Mangaonkar, A. A., Desai, P., Dezern, A. E., Garnier, et al
ELSEVIER.2024: 354-355
- **Contemporary Approach to The Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes- Recommendations from The International Consortium for MDS (icMDS).** *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*
Aakash, F., Gisriel, S. D., Zeidan, A. M., Bennett, J. M., Bejar, R., Bewersdorf, J. P., Borate, U. M., Boultonwood, J., Brunner, A. M., Buckstein, R., Carraway, H., Churpek, J. E., Daver, et al
2024: 100615

- **Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications.** *Blood*
Bernard, E., Hasserjian, R. P., Greenberg, P. L., Arango Ossa, J. E., Creignou, M., Tuechler, H., Gutierrez-Abril, J., Domenico, D., Medina-Martinez, J. S., Levine, M. F., Liosis, K., Farnoud, N., Sirenko, et al
2024
- **Towards a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).** *HemaSphere*
Efficace, F., Buckstein, R., Abel, G. A., Giesinger, J. M., Fenaux, P., Bewersdorf, J. P., Brunner, A. M., Bejar, R., Borate, U., DeZern, A. E., Greenberg, P., Roboz, G. J., Savona, et al
2024; 8 (5): e69
- **Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.** *Blood*
Sirenko, M., Bernard, E., Creignou, M., Domenico, D., Farina, A., Arango Ossa, J. E., Kosmider, O., Hasserjian, R. P., Jädersten, M., Germing, U., Sanz, G. F., van de Loosdrecht, A. A., Gurnari, et al
2024
- **p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.** *American journal of clinical pathology*
Brar, N., Lawrence, L., Fung, E., Zehnder, J. L., Greenberg, P. L., Mannis, G. N., Zhang, T. Y., Gratzinger, D., Oak, J., Silva, O., Kurzer, J., Tan, B., Menke, et al
2024
- **Shared and distinct mechanisms of UBA1 inactivation across different diseases.** *The EMBO journal*
Collins, J. C., Magaziner, S. J., English, M., Hassan, B., Chen, X., Balandá, N., Anderson, M., Lam, A., Fernandez-Pol, S., Kwong, B., Greenberg, P. L., Terrier, B., Likhite, et al
2024
- **How we reduce and treat post-transplant relapse of MDS.** *Blood*
Mina, A., Greenberg, P. L., Deeg, H. J.
2024
- **The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.** *Leukemia research*
Khanna, V., Lu, R., Kumar, J., Molina, A., Stehr, H., Spiteri, E., Spinner, M., Silva, O., Fernandez-Pol, S., Tan, B., Greenberg, P. L.
2023; 136: 107433
- **Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study**
Garcia-Manero, G., Ooi, M., Lao, Z., Gill, H., Abaza, Y., Stahl, M., Haque, T., DeZern, A. E., Greenberg, P. L., Pelletier, M., Singh, A., Carreon, D., Beaulieu, et al
AMER SOC HEMATOLOGY.2023
- **Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).** *Blood reviews*
Stahl, M., Bewersdorf, J. P., Xie, Z., Porta, M. G., Komrokji, R., Xu, M. L., Abdel-Wahab, O., Taylor, J., Steensma, D. P., Starczynowski, D. T., Sekeres, M. A., Sanz, G., Sallman, et al
2023: 101128
- **Prognostication and risk stratification of patients with myelodysplastic syndromes.** *Blood*
DeZern, A., Greenberg, P. L.
2023
- **A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)**
Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R., Sekeres, M., Della Porta, M., Cazzola, M., DeZern, A., Roboz, G., Steensma, D., Van De Loosdrecht, A., Malcovati, et al
PERGAMON-ELSEVIER SCIENCE LTD.2023
- **GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES**
Bernard, E., Hasserjian, R., Greenberg, P., Ossa, J., Creignou, M., Nannya, Y., Tuechler, H., Medina-Martinez, J., Levine, M., Jadersten, M., Germing, U., Sanz, G., Van De Loosdrecht, et al
PERGAMON-ELSEVIER SCIENCE LTD.2023

- **ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS - AN ANALYSIS OF THE IWG-PM DATABASE**
Pfeilstoecker, M., Tuechler, H., Ades, L., Cermak, J., Chermat, F., Della Porta, M., Fenaux, P., Garcia-Manero, G., Germing, U., Haase, D., Kuendgen, A., Luebbert, M., Magalhaes, et al
PERGAMON-ELSEVIER SCIENCE LTD.2023
- **Myelodysplastic syndromes, thy name is heterogeneity.** *British journal of haematology*
Greenberg, P. L.
2023
- **Recent Clinical and Molecular Advances for the Classification of Myelodysplastic Neoplasms.** *Journal of the National Comprehensive Cancer Network : JNCCN*
DeZern, A. E., Greenberg, P. L.
2022; 20 (12): 1280-1283
- **Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories**
Pfeilstoecker, M., Tuechler, H., Ades, L., Cermak, J., Chermat, F., Della Porta, M. G., Fenaux, P., Garcia-Manero, G., Germing, U., Haase, D., Kuendgen, A., Luebbert, M., Magalhaes, et al
AMER SOC HEMATOLOGY.2022: 6976-6978
- **Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS**
Sirenko, M., Bernard, E., Beck, D. B., Creignou, M., Domenico, D., Farina, A., Arango, J. E., Kosmider, O., Hasserjian, R. P., Jadersten, M., Germing, U., Sanz, G., van de Loosdrecht, et al
AMER SOC HEMATOLOGY.2022: 9785-9788
- **Correlation of Mutational Profiles and Cytogenetics with Morphologic Dysplasia in Myelodysplastic Syndromes**
Kumar, J., Khanna, V., Lu, R., Stehr, H., Spinner, M. A., Silva, O., Fernandez-Pol, S., Oak, J. S., Greenberg, P. L., Tan, B.
AMER SOC HEMATOLOGY.2022: 4053-4055
- **Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.** *Leukemia*
Zeidan, A. M., Bewersdorf, J. P., Buckstein, R., Sekeres, M. A., Steensma, D. P., Platzbecker, U., Loghavi, S., Boultonwood, J., Bejar, R., Bennett, J. M., Borate, U., Brunner, A. M., Carraway, et al
2022
- **An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS).** *Blood advances*
Stahl, M., Abdel-Wahab, O., Wei, A. H., Savona, M. R., Xu, M. L., Xie, Z., Taylor, J., Starczynowski, D. T., Sanz, G. F., Sallman, D. A., Santini, V., Roboz, G. J., Patnaik, et al
2022
- **Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.** *Blood*
Zeidan, A. M., Platzbecker, U., Garcia-Manero, G., Sekeres, M. A., Fenaux, P., DeZern, A. E., Greenberg, P. L., Savona, M. R., Jurcic, J. G., Verma, A., Mufti Obe, G. J., Buckstein, R. J., Santini, et al
2022
- **Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.** *NEJM evidence*
Bernard, E., Tuechler, H., Greenberg, P. L., Hasserjian, R. P., Arango Ossa, J. E., Nannya, Y., Devlin, S. M., Creignou, M., Pinel, P., Monnier, L., Gundem, G., Medina-Martinez, J. S., Domenico, et al
2022; 1 (7): EVIDoa2200008
- **Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.** *Leukemia*
Komrokji, R. S., Platzbecker, U., Fenaux, P., Zeidan, A. M., Garcia-Manero, G., Mufti, G. J., Santini, V., Diez-Campelo, M., Finelli, C., Jurcic, J. G., Greenberg, P. L., Sekeres, M. A., DeZern, et al
2022
- **NCCN Guidelines Insights: Myelodysplastic Syndromes, Version 3.2022.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Greenberg, P. L., Stone, R. M., Al-Kali, A., Bennett, J. M., Borate, U., Brunner, A. M., Chai-Ho, W., Curtin, P., de Castro, C. M., Deeg, H. J., DeZern, A. E., Dinner, S., Foucar, et al
2022; 20 (2): 106-117

- **Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.** *Blood advances*
Gerds, A. T., Scott, B. L., Greenberg, P. L., Lin, T. L., Pollyea, D. A., Verma, A. K., Dail, M., Feng, Y., Green, C., Ma, C., Medeiros, B. C., Yan, M., Yousefi, et al
1800
- **MDS and MDS/MPN Genomic Subgroups Demonstrate Differential Ex Vivo Drug Sensitivity**
Spinner, M. A., Schaffert, S. A., Stehr, H., TSantaguida, M., Kita, R., Aleshin, A., Zehnder, J. L., Greenberg, P. L.
AMER SOC HEMATOLOGY.2021
- **COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)**
Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R., Sekeres, M., Della Porta, M., Cazzola, M., Malcovati, L., Dezern, A., Roboz, G., Steensma, D., Haase, et al
PERGAMON-ELSEVIER SCIENCE LTD.2021: S20-S21
- **Metchnikoff's inflamed legacy: the dysplastic nature of myelodysplastic syndrome's innate immunity.** *Haematologica*
Greenberg, P. L.
2021
- **Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.** *Leukemia*
Steensma, D. P., Wermke, M., Klimek, V. M., Greenberg, P. L., Font, P., Komrokji, R. S., Yang, J., Brunner, A. M., Carraway, H. E., Ades, L., Al-Kali, A., Alonso-Dominguez, J. M., Alfonso-Pierola, et al
2021
- **Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)** *NATURE MEDICINE*
Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., Levine, M. F., Arango, J. E., Zhou, et al
2021
- **A Retrospective Analysis From Patients Treated in The MEDALIST Study: Safety and Efficacy Of Luspatercept Treatment In Patients With Myelodysplastic Syndrome/Myeloproliferative Neoplasm With Ring Sideroblasts And Thrombocytosis**
Komrokji, R. S., Platzbecker, U., Fenaux, P., Garcia-Manero, G., Mufti, G. J., Santini, V., Diez-Campelo, M., Finelli, C., Jurcic, J. G., Greenberg, P. L., Sekeres, M. A., Zeidan, A. M., Dezern, et al
WILEY.2021: 67-68
- **Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations.** *Blood advances*
Feurstein, S., Adegunsoye, A., Mojsilovic, D., Vij, R., West DePersia, A. H., Rajagopal, P. S., Osman, A., Collins, R. H., Kim, R. H., Gore, S. D., Greenberg, P., Godley, L. A., Li, et al
2020; 4 (19): 4873–86
- **Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.** *Leukemia*
Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R. S., Sekeres, M. A., Della Porta, M. G., Cazzola, M., DeZern, A. E., Roboz, G. J., Steensma, D. P., Van de Loosdrecht, A. A., Schlenk, et al
2020
- **SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM).** *Blood*
Malcovati, L., Stevenson, K., Papaemmanuil, E., Neubergh, D., Bejar, R., Boultonwood, J., Bowen, D. T., Campbell, P. J., Ebert, B. L., Fenaux, P., Haferlach, T., Heuser, M., Jansen, et al
2020
- **Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.** *Annals of internal medicine*
Angelucci, E., Li, J., Greenberg, P., Wu, D., Hou, M., Montano Figueroa, E. H., Rodriguez, M. G., Dong, X., Ghosh, J., Izquierdo, M., Garcia-Manero, G., TELESTO Study Investigators
2020
- **Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey.** *Leukemia & lymphoma*

- Pine, A. B., Chokr, N., Stahl, M., Steensma, D. P., Sekeres, M. A., Litzow, M. R., Luger, S. M., Stone, R. M., Greenberg, P. L., Bejar, R., Bewersdorf, J. P., Gore, S. D., Zeidan, et al
2020: 1–10
- **Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation.** *Cytometry. Part B, Clinical cytometry*
Behbehani, G. K., Finck, R., Samusik, N., Sridhar, K., Fantl, W. J., Greenberg, P. L., Nolan, G. P.
2020
 - **Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.** *The New England journal of medicine*
Fenaux, P. n., Platzbecker, U. n., Mufti, G. J., Garcia-Manero, G. n., Buckstein, R. n., Santini, V. n., Díez-Campelo, M. n., Finelli, C. n., Cazzola, M. n., Ilhan, O. n., Sekeres, M. A., Falantes, J. F., Arrizabalaga, et al
2020; 382 (2): 140–51
 - **Myelodysplastic syndromes: moving towards personalized management.** *Haematologica*
Hellström-Lindberg, E. n., Tobiasson, M. n., Greenberg, P. n.
2020
 - **Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.** *Leukemia & lymphoma*
Azizi, A. n., Ediriwickrema, A. n., Dutta, R. n., Patel, S. A., Shomali, W. n., Medeiros, B. n., Iberri, D. n., Gottlib, J. n., Mannis, G. n., Greenberg, P. n., Majeti, R. n., Zhang, T. n.
2020: 1–8
 - **Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms.** *Blood advances*
Spinner, M. A., Aleshin, A. n., Santaguida, M. T., Schaffert, S. A., Zehnder, J. L., Patterson, A. S., Gekas, C. n., Heiser, D. n., Greenberg, P. L.
2020; 4 (12): 2768–78
 - **Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions** *HAEMATOLOGICA*
Valent, P., Orazi, A., Savona, M. R., Patnaik, M. M., Onida, F., van de Loosdrecht, A. A., Haase, D., Haferlach, T., Elena, C., Pleyer, L., Kern, W., Pemovska, T., Vladimer, et al
2019; 104 (10): 1935–49
 - **MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-beta pathways.** *Blood advances*
Youn, M., Huang, H., Chen, C., Kam, S., Wilkes, M. C., Chae, H., Sridhar, K. J., Greenberg, P. L., Glader, B., Narla, A., Lin, S., Sakamoto, K. M.
2019; 3 (18): 2751–63
 - **TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups** *LEUKEMIA*
Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., Ebert, B. L., Garcia-Manero, G., Haferlach, C., Haferlach, T., Kern, W., Ogawa, S., Nagata, et al
2019; 33 (7): 1747–58
 - **Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review** *BRITISH JOURNAL OF HAEMATOLOGY*
Park, S., Greenberg, P., Yucel, A., Farmer, C., O'Neill, F., Brandao, C., Fenaux, P.
2019; 184 (2): 134–60
 - **Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study.** *JAMA oncology*
Atallah, E. n., Logan, B. n., Chen, M. n., Cutler, C. n., Deeg, J. n., Jacoby, M. n., Champlin, R. n., Nishihori, T. n., Confer, D. n., Gajewski, J. n., Farnia, S. n., Greenberg, P. n., Warlick, et al
2019
 - **Single-Cell Mutational Profiling Describes the Molecular Heterogeneity of Clonal Evolution in MDS during Therapy and Relapse**
Aleshin, A., Durruthy-Durruthy, R., Medeiros, B. C., Eastburn, D. J., Greenberg, P. L.
AMER SOC HEMATOLOGY.2018
 - **PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis**
Gerds, A. T., Scott, B. L., Greenberg, P. L., Khaled, S. K., Lin, T. L., Pollyea, D. A., Verma, A., Dail, M., Green, C., Ma, C., Medeiros, B. C., Phuong, P., Wenger, et al

AMER SOC HEMATOLOGY.2018

- **Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance** *GENES CHROMOSOMES & CANCER*
Schanz, J., Sole, F., Mallo, M., Luno, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., Fonatsch, C., Pfeilstoecker, M., Noesslinger, T., Valent, et al
2018; 57 (11): 547–56
- **Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy** *BLOOD ADVANCES*
Aleshin, A., Greenberg, P. L.
2018; 2 (20): 2787–97
- **Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS** *LEUKEMIA RESEARCH*
Miyazaki, Y., Tuechler, H., Sanz, G., Schanz, J., Garcia-Manero, G., Sole, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Malcovati, et al
2018; 73: 51–57
- **Single-cell mutational profiling of clonal evolution in myelodysplastic syndromes (MDS) during therapy and disease progression**
Aleshin, A., Greenberg, P. L., Medeiros, B. C., Heiser, D., Santaguida, M., Prashad, S., Durruthy-Durruthy, R., Eastburn, D. J.
AMER ASSOC CANCER RESEARCH.2018
- **Recurrent drug sensitivity patterns in myelodysplastic syndrome patients are recapitulated by ex vivo drug response profiling**
Aleshin, A., Medeiros, B. C., Kamble, S., Heiser, D., Santaguida, M., Prashad, S., Greenberg, P. L.
AMER ASSOC CANCER RESEARCH.2018
- **Distinct Transcriptomic and Exomic Abnormalities Within Myelodysplastic Syndrome Marrow Cells** *Leukemia & Lymphoma*
Im, H., Rao, V., Sridhar, K., Bentley, J., Mishra, T., Chen, R., Hall, J., Graber, A., Zhang, Y., Xiao, L., Mias, G., Snyder, M. P., Greenberg, et al
2018: 1-11
- **Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions** *ONCOTARGET*
Valent, P., Orazi, A., Steensma, D. P., Ebert, B. L., Haase, D., Malcovati, L., van de Loosdrecht, A. A., Haferlach, T., Westers, T. M., Wells, D. A., Giagounidis, A., Loken, M., Orfao, et al
2017; 8 (43): 73483–500
- **A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB ALONE AND IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES**
Gerds, A. T., Scott, B. L., Greenberg, P., Verma, A., Phuong, P., Yan, M., Dail, M., Green, C., Li, C., Krishnan, K., Donnellan, W.
FERRATA STORTI FOUNDATION.2017: 262
- **Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)** *JOURNAL OF HEMATOLOGY & ONCOLOGY*
Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mittelman, M., Muus, P., Nimer, S. D., Hellstrom-Lindberg, E., Powell, B. L., Guerci-Bresler, A., Sekeres, M. A., Deeg, H., del Canizo, et al
2017; 10: 131
- **CHROMOSOMAL ABERRATIONS IN THERAPY-RELATED MYELODYSPLASTIC SYNDROMES - RELATIONS TO PRIMARY DISEASE, THERAPY AND PROGNOSTIC SIGNIFICANCE**
Nomdedeu, M., Tuechler, H., Kuendgen, A., Sole, F., Schanz, J., Hildebrandt, B., Grau, J., Pereira, A., Garcia-Manero, G., Sekeres, M. A., Komrokji, R. S., Voso, M. T., List, et al
PERGAMON-ELSEVIER SCIENCE LTD.2017: S32–S33
- **The classical nature of distinctive CMML monocytes** *BLOOD*
Greenberg, P. L.
2017; 129 (13): 1745–46
- **The Impact of Somatic and Germline Mutations in MDS and Related Disorders** *J Nat Comp Canc Network*
Bejar, R., Greenberg, P. L.
2017; 15: 137-141
- **Myelodysplastic Syndromes, Version 2.2017 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*

- Greenberg, P. L., Stone, R. M., Al-Kali, A., Barta, S. K., Bejar, R., Bennett, J. M., Carraway, H., De Castro, C. M., Deeg, H. J., DeZern, A. E., Fathi, A. T., Frankfurt, O., Gaensler, et al
2017; 15 (1): 60-87
- **Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)**
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Navada, S. C., Baer, M. R., Raza, A., Greenberg, P., Kreuzer, K., Hiwase, D. K., Roboz, G. J., Santini, V., Platzbecker, U., Petrone, et al
AMER SOC HEMATOLOGY.2016
 - **Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)**
Kuendgen, A., Tuechler, H., Nomdedeu, M., Haase, D., Garcia-Manero, G., Komrokji, R. S., Sole, F., Sekeres, M. A., Della Porta, M., List, A. F., Cazzola, M., DeZern, A. E., Roboz, et al
AMER SOC HEMATOLOGY.2016
 - **KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.** *Leukemia research*
Swords, R. T., Greenberg, P. L., Wei, A. H., Durrant, S., Advani, A. S., Hertzberg, M. S., Lewis, I. D., Rivera, G., Gratzinger, D., Fan, A. C., Felsher, D. W., Cortes, J. E., Watts, et al
2016; 50: 123-131
 - **Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis** *BRITISH JOURNAL OF HAEMATOLOGY*
Park, S., Fenaux, P., Greenberg, P., Mehta, B., Callaghan, F., Kim, C., Tomita, D., Xu, H.
2016; 174 (5): 730-747
 - **Time-dependent changes in mortality and transformation risk in MDS.** *Blood*
Pfeilstöcker, M., Tuechler, H., Sanz, G., Schanz, J., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Malcovati, et al
2016; 128 (7): 902-910
 - **Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.** *Blood*
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, et al
2016
 - **Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial** *LANCET ONCOLOGY*
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., Gaidano, G., Scott, B. L., Greenberg, P., Platzbecker, U., Steensma, D. P., Kambhampati, S., Kreuzer, et al
2016; 17 (4): 496-508
 - **Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome** *LEUKEMIA & LYMPHOMA*
Narayan, R., Garcia, J. S., Percival, M. M., Berube, C., Coutre, S., Gotlib, J., Greenberg, P., Liedtke, M., Hewitt, R., Regan, K., Williamson, C., Doykan, C., Cardone, et al
2016; 57 (3): 609-615
 - **The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.** *Clinical cancer research*
Maxson, J. E., Luty, S. B., Macmaniman, J. D., Paik, J. C., Gotlib, J., Greenberg, P., Bahamadi, S., Savage, S. L., Abel, M. L., Eide, C. A., Loriaux, M. M., Stevens, E. A., Tyner, et al
2016; 22 (3): 757-764
 - **Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.** *British journal of haematology*
Prebet, T., Sun, Z., Ketterling, R. P., Zeidan, A., Greenberg, P., Herman, J., Juckett, M., Smith, M. R., Mallick, L., Paietta, E., Czader, M., Figueroa, M., Gabilove, et al
2016; 172 (3): 384-391
 - **Immune checkpoint pathways: perspectives on myeloid malignancies** *LEUKEMIA & LYMPHOMA*
Rivera, G. A., Behbahan, I. S., Greenberg, P. L.

2016; 57 (5): 995-1001

- **Cytogenetic classification according to IPSS/-R is possible from peripheral blood in patients with Myelodysplastic Syndromes**
Braulke, F., Platzbecker, U., Mueller-Thomas, C., Goetze, K., Germing, U., Bruemmerndorf, T. H., Nolte, F., Hofmann, W., Giagounidis, A. N., Luebbert, M., Greenberg, P. L., Bennett, J. M., Sole, et al
KARGER.2016: 171
- **Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age**
Atallah, E., Horowitz, M. M., Logan, B., Chen, M., Boo, M. J., Cutler, C. S., Deeg, J., Gajewski, J. L., Confer, D. L., Farnia, S., Greenberg, P., Warlick, E., Weisdorf, et al
AMER SOC HEMATOLOGY.2015
- **Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes**
Schanz, J., Tuechler, H., Sole, F., Sanz, G., Garcia-Manero, G., Le Beau, M. M., Bennett, J. M., Slovak, M. L., Fenaux, P., Malcovati, L., Cazzola, M., Valent, P., Ohyashiki, et al
AMER SOC HEMATOLOGY.2015
- **An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)**
Kuendgen, A., Tuechler, H., Nomdedeu, M., Garcia-Manero, G., Komrokji, R. S., Sekeres, M. A., Della Porta, M., List, A. F., Cazzola, M., DeZern, A. E., Roboz, G. J., Steensma, D. P., van de Loosdrecht, et al
AMER SOC HEMATOLOGY.2015
- **Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee**
Bejar, R., Papaemmanuil, E., Haferlach, T., Garcia-Manero, G., Maciejewski, J. P., Sekeres, M. A., Walter, M. J., Graubert, T. A., Cazzola, M., Malcovati, L., Ogawa, S., Fenaux, P., Hellstrom-Lindberg, et al
AMER SOC HEMATOLOGY.2015
- **Frequency of del(12p) is Commonly Underestimated in Myelodysplastic Syndromes: Results from a German Diagnostic Study in Comparison with an International Control Group** *GENES CHROMOSOMES & CANCER*
Braulke, F., Mueller-Thomas, C., Goetze, K., Platzbecker, U., Germing, U., Hofmann, W., Giagounidis, A. A., Luebbert, M., Greenberg, P. L., Bennett, J. M., Sole, F., Slovak, M. L., Ohyashiki, et al
2015; 54 (12): 809-817
- **Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial** *LANCET HAEMATOLOGY*
Platzbecker, U., Wong, R. S., Verma, A., Abboud, C., Araujo, S., Chiou, T., Feigert, J., Yeh, S., Goetze, K., Gorin, N., Greenberg, P., Kambhampati, S., Kim, et al
2015; 2 (10): E417-E426
- **Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.** *The Lancet. Haematology*
Platzbecker, U., Wong, R. S., Verma, A., Abboud, C., Araujo, S., Chiou, T. J., Feigert, J., Yeh, S. P., Götze, K., Gorin, N. C., Greenberg, P., Kambhampati, S., Kim, et al
2015; 2 (10): e417-26
- **Prognostic significance of rare single abnormalities in Myelodysplastic Syndromes**
Schanz, J., Tuechler, H., Sole, F., Sanz, G., Garcia-Manero, G., LeBeau, M., Bennett, J. M., Slovak, M. L., Fenaux, P., Malcovati, L., Cazzola, M., Pfeilstoecker, M., Valent, et al
KARGER.2015: 31
- **Underestimation of 12p-deletion in myelodysplastic syndromes? Results from a German diagnostic study in comparison with an international control group**
Braulke, F., Mueller-Thomas, C., Goetze, K., Platzbecker, U., Germing, U., Hofmann, W., Giagounides, A. N., Luebbert, M., Greenberg, P. L., Bennett, J. M., Sole, F., Slovak, M. L., Ohyashiki, et al
KARGER.2015: 33
- **In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs** *MAYO CLINIC PROCEEDINGS*

- Tefferi, A., Rajkumar, S., Gertz, M. A., Kyle, R. A., Kantarjian, H., Allison, J., Bast, R. C., Cortes, J., Fidler, I. J., Freireich, E., Gutterman, J., Hong, W., Hortobagyi, et al
2015; 90 (8): 996–1000
- **Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).** *Leukemia*
Della Porta, M. G., Tuechler, H., Malcovati, L., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, et al
2015; 29 (7): 1502-1513
 - **Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy** *HEMATOLOGICAL ONCOLOGY*
Silverman, L. R., Greenberg, P., Raza, A., Olnes, M. J., Holland, J. F., Reddy, P., Maniar, M., Wilhelm, F.
2015; 33 (2): 57-66
 - **OVERALL SURVIVAL (OS) AND BASELINE DISEASE CHARACTERISTICS IN MDS PATIENTS WITH PRIMARY HMA FAILURE IN A RANDOMIZED, CONTROLLED, PHASE III STUDY OF RIGOSERTIB**
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D., Kreuzer, K., Godley, et al
FERRATA STORTI FOUNDATION.2015: 238
 - **CORRELATION OF OVERALL SURVIVAL (OS) WITH BONE MARROW BLAST (BMBL) RESPONSE IN PATIENTS (PTS) WITH MYELODYSPLASTIC SYNDROMES (MDS)**
Silverman, L., Fenaux, P., Greenberg, P., Demakos, E., Santini, V., Seymour, J., Navada, S., Petrone, M., Snyder, B., Azarnia, N., Garcia-Manero, G.
FERRATA STORTI FOUNDATION.2015: 242
 - **PROGNOSTIC AND PREDICTIVE VALUE OF IPSS-R IN ASSESSING OVERALL SURVIVAL (OS) IN A PHASE III STUDY OF RIGOSERTIB IN SECOND-LINE HIGHER-RISK (HR) MDS PATIENTS**
Silverman, L., Fenaux, P., Al-Kali, A., Baer, M., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D., Kreuzer, K., Godley, et al
FERRATA STORTI FOUNDATION.2015: 492
 - **Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib.**
Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., Gaidano, G., Silverman, L. R., Scott, B. L., Greenberg, P., Platzbecker, U., Steensma, D. P., Kreuzer, K. A., Godley, et al
AMER SOC CLINICAL ONCOLOGY.2015
 - **Correlation of overall survival (OS) with bone marrow blast (BMBL) response in patients (pts) with myelodysplastic syndrome**
Silverman, L. R., Fenaux, P., Greenberg, P., Demakos, E. P., Santini, V., Seymour, J., Navada, S., Petrone, M. E., Snyder, B. R., Azarnia, N., Garcia-Manero, G.
AMER SOC CLINICAL ONCOLOGY.2015
 - **Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients.**
Silverman, L. R., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., Gaidano, G., Scott, B. L., Greenberg, P., Platzbecker, U., Steensma, D. P., Kreuzer, K. A., Godley, et al
AMER SOC CLINICAL ONCOLOGY.2015
 - **RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS)**
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D. P., Kambhampati, S., Kreuzer, et al
PERGAMON-ELSEVIER SCIENCE LTD.2015: S57–S58
 - **BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION?**
Silverman, L. R., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D. P., Kambhampati, S., Kreuzer, et al
PERGAMON-ELSEVIER SCIENCE LTD.2015: S44–S45

- **MDS prognostic scoring systems - Past, present, and future** *BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY*
Jonas, B. A., Greenberg, P. L.
2015; 28 (1): 3-13
- **Myelodysplastic Syndromes, Version 2.2015** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Greenberg, P. L., Stone, R. M., Bejar, R., Bennett, J. M., Bloomfield, C. D., Borate, U., De Castro, C. M., Deeg, H. J., DeZern, A. E., Fathi, A. T., Frankfurt, O., Gaensler, K., Garcia-Manero, et al
2015; 13 (3): 261-272
- **Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34(+)FISH:results from a German diagnostic study in comparison with an international control group** *HAEMATOLOGICA*
Braulke, F., Platzbecker, U., Mueller-Thomas, C., Goetze, K., Germing, U., Bruemmendorf, T. H., Nolte, F., Hofmann, W., Giagounidis, A. A., Luebbert, M., Greenberg, P. L., Bennett, J. M., Sole, et al
2015; 100 (2): 205-213
- **Synergistic Interactions of Molecular and Clinical Advances for Characterizing the Myelodysplastic Syndromes** *J Nat Compr Canc Network*
Greenberg, P. L.
2015; 13 (7): 829-832
- **p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study**
Saft, L., Li, J., Greenberg, P. L., Sekeres, M. A., Sanz, G. F., Dreyfus, F., Fenaux, P., Swern, A. S., Sugrue, M. M., Hellstrom-Lindberg, E.
AMER SOC HEMATOLOGY.2014
- **Transcriptomic Evaluation of CD34+Marrow Cells from Myelodysplastic Syndrome (MDS) Patients**
Im, H., Rao, V., Sridhar, K., Chen, R., Mias, G., Zhang, Y., Xiao, L., Snyder, M. P., Greenberg, P. L.
AMER SOC HEMATOLOGY.2014
- **Profiling Myelodysplastic Syndromes By Mass Cytometry Demonstrates Distinct Immunophenotypic Aberrancies in Stem and Progenitor Populations**
Behbehani, G. K., Finck, R., Samusik, N., Gherardini, P., Sridhar, K. J., Fantl, W. J., Greenberg, P. L., Nolan, G. P.
AMER SOC HEMATOLOGY.2014
- **TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee**
Bejar, R., Papaemmanuil, E., Haferlach, T., Garcia-Manero, G., Maciejewski, J. P., Sekeres, M. A., Walter, M. J., Graubert, T. A., Cazzola, M., Malcovati, L., Campbell, P. J., Ogawa, S., Boultonwood, et al
AMER SOC HEMATOLOGY.2014
- **KB004, a Novel Non-Fucosylated Humanized (R) Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies**
Swords, R. T., Wei, A. H., Durrant, S., Advani, A. S., Hertzberg, M. S., Lewis, I. D., Greenberg, P. L., Cortes, J. E., Yarranton, G. T., Walling, J. M., Lancet, J. E.
AMER SOC HEMATOLOGY.2014
- **Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)**
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., Gaidano, G., Scott, B. L., Greenberg, P. L., Platzbecker, U., Steensma, D. P., Kambhampati, S., Kreuzer, et al
AMER SOC HEMATOLOGY.2014
- **Genomic Microarray Alterations Add Prognostic Power to the IPSS-R in MDS with Normal Karyotype**
Mallo, M., Tuechler, H., Shih, L., Ogawa, S., Sanada, M., Lin, T., Ganster, C., Shireshan, K., Haase, D., Lopez-Pavia, M., Cervera, J., Such, E., Arenillas, et al
AMER SOC HEMATOLOGY.2014
- **Relationship of Bone Marrow Blast (BMBl) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs)**
Silverman, L. R., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., Gaidano, G., Scott, B. L., Greenberg, P. L., Platzbecker, U., Steensma, D. P., Kambhampati, S., Kreuzer, et al
AMER SOC HEMATOLOGY.2014

- **Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival.** *American journal of clinical pathology*
Johnson, R. C., Kurzer, J. H., Greenberg, P. L., Gratzinger, D.
2014; 142 (6): 795-802
- **Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS** *BRITISH JOURNAL OF HAEMATOLOGY*
Zeidan, A. M., Lee, J., Prebet, T., Greenberg, P., Sun, Z., Juckett, M., Smith, M. R., Paietta, E., Gabrilove, J., Erba, H. P., Katterling, R. P., Tallman, M. S., Gore, et al
2014; 167 (1): 62-68
- **Is IPSS/IPSS-R cytogenetic classification possible from peripheral blood in MDS patients? Comparative results from a prospective German diagnostic study with the data set of an international collaboration**
Braulke, F., Platzbecker, U., Mueller-Thomas, C., Goetze, K., Germing, U., Bruemendorf, T. H., Nolte, F., Hofmann, W., Giagounidis, A. N., Luebbert, M., Greenberg, P. L., Bennett, J. M., Sole, et al
KARGER.2014: 235-36
- **MYELODYSPLASTIC SYNDROMES: OLD AND NEW CLASSIFICATION AND PROGNOSTIC SYSTEMS**
Greenberg, P.
PERGAMON-ELSEVIER SCIENCE LTD.2014: S4
- **Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes** *BRITISH JOURNAL OF HAEMATOLOGY*
Zeidan, A. M., Lee, J., Prebet, T., Greenberg, P., Sun, Z., Juckett, M., Smith, M. R., Paietta, E., Gabrilove, J., Erba, H. P., Tallman, M. S., Gore, S. D.
2014; 166 (3): 352-359
- **Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)** *BLOOD CANCER JOURNAL*
Sekeres, M. A., Swern, A. S., Fenaux, P., Greenberg, P. L., Sanz, G. F., Bennett, J. M., Dreyfus, F., List, A. F., Li, J. S., Sugrue, M. M.
2014; 4: e242
- **Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905** *JOURNAL OF CLINICAL ONCOLOGY*
Prebet, T., Sun, Z., Figueroa, M. E., Ketterling, R., Melnick, A., Greenberg, P. L., Herman, J., Juckett, M., Smith, M. R., Malick, L., Paietta, E., Czader, M., Litzow, et al
2014; 32 (12): 1242-?
- **Mesenchymal Stromal Cell Density is Increased in Higher Grade Myelodysplastic Syndromes and Independently Predicts Survival.** *J Clin Path*
Johnson, R., Kurzer, J., Greenberg, P., Gratzinger, D.
2014; 142: 795-802
- **Update on Myelodysplastic Syndromes Classification and Prognosis.** *Surgical pathology clinics*
Gratzinger, D., Greenberg, P. L.
2013; 6 (4): 693-728
- **IL1RAP as functionally relevant target for stem-cell directed therapy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).**
Barreyro, L., Mitchell, K., Will, B., Bartholdy, B., Zhou, L., Todorova, T., Stanley, R., Ben-Neriah, S., Montagna, C., Parekh, S., Pellagatti, A., Boultonwood, J., Paietta, et al
AMER ASSOC CANCER RESEARCH.2013
- **Monosomal karyotype in MDS: explaining the poor prognosis?** *LEUKEMIA*
Schanz, J., Tuechler, H., Sole, F., Mallo, M., Luno, E., Cervera, J., Grau, J., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., Steidl, C., Fonatsch, C., Pfeilstoecker, et al
2013; 27 (10): 1988-1995
- **Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.** *Journal of clinical oncology*
Koreth, J., Pidala, J., Perez, W. S., Deeg, H. J., Garcia-Manero, G., Malcovati, L., Cazzola, M., Park, S., Itzykson, R., AdeS, L., Fenaux, P., Jadersten, M., Hellstrom-Lindberg, et al

2013; 31 (21): 2662-2670

- **The Multifaceted Nature of Myelodysplastic Syndromes: Clinical, Molecular, and Biological Prognostic Features** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Greenberg, P. L.
2013; 11 (7): 877-885
- **Myelodysplastic syndromes: clinical practice guidelines in oncology.** *Journal of the National Comprehensive Cancer Network*
Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., Borate, U., De Castro, C. M., Deeg, H. J., Frankfurt, O., Gaensler, K., Garcia-Manero, G., Gore, S. D., Head, D., Komrokji, et al
2013; 11 (7): 838-874
- **Myelodysplastic Syndromes** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., Borate, U., De Castro, C. M., Deeg, H. J., Frankfurt, O., Gaensler, K., Garcia-Manero, G., Gore, S. D., Head, D., Komrokji, et al
2013; 11 (7): 838-874
- **ESTIMATION OF THE RELATIONSHIP BETWEEN SERUM FERRITIN AND LIVER IRON CONCENTRATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES**
Gattermann, N., Greenberg, P., Urabe, A., El-Ali, A., Martin, N., Porter, J.
FERRATA STORTI FOUNDATION.2013: 178
- **PLACEBO-CONTROLLED, RANDOMIZED, PHASE I/II TRIAL OF THE THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG IN THROMBOCYTOPENIC PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES OR ACUTE MYELOID LEUKEMIA**
Platzbecker, U., Wong, R., Verma, A., Abboud, C., Araujo, S., Chiou, T., Feigert, J., Yeh, S., Goetze, K., Gorin, N., Greenberg, P., Kambhampati, S., Kim, et al
FERRATA STORTI FOUNDATION.2013: 455
- **Application of the French prognostic score (FPS) to assess overall survival (OS) in a US-based cohort of patients (pts) treated with azacitidine (Aza).**
Zeidan, A., Sun, Z., Prebet, T., Greenberg, P., Juckett, M., Smith, M., Paietta, E., Gabrilove, J., Erba, H. P., Gore, S., Tallman, M. S., Eastern Cooperative Oncology Grp
AMER SOC CLINICAL ONCOLOGY.2013
- **Evaluation of hematopoietic stem/progenitor cells in MDS reveals novel pathogenic mechanisms**
Park, C. Y., Pang, W. W., Chung, S. S., Pluvinage, J. V., Price, E. A., Sridhar, K., Arber, D. A., Greenberg, P. L., Schrier, S. L., Weissman, I. L.
PERGAMON-ELSEVIER SCIENCE LTD.2013: S12-S13
- **Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDSWith del(5q) in MDS-003 and MDS-004: A retrospective analysis**
Sekeres, M., Swern, A., Fenaux, P., Greenberg, P., Sanz, G., Bennett, J., Dreyfus, F., Cazzola, M., List, A., Garcia-Manero, G., Li, J., Sugrue, M.
PERGAMON-ELSEVIER SCIENCE LTD.2013: S69-S70
- **Revised International Prognostic Scoring System (IPSS-R) for primary treated myelodysplastic syndromes (MDS) patients: A report from the IWG-PM**
Sekeres, M., Ades, L., Tuechler, H., Sanz, G., Levis, A., Malcovati, L., Cazzola, M., Magalhaes, S. M., Luebbert, M., Haase, D., Schanz, J., Cermak, J., Garcia-Manero, et al
PERGAMON-ELSEVIER SCIENCE LTD.2013: S74-S75
- **Revised International Prognostic Scoring System (IPSS-R) for MDS: Update**
Greenberg, P., Tuechler, H.
PERGAMON-ELSEVIER SCIENCE LTD.2013: S3
- **Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.** *Haematologica*
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., Greenberg, P., Zhang, B., Liedtke, M., Berube, C., Levine, R., Mitchell, B. S., Medeiros, et al
2013; 98 (4): 591-596
- **Randomized, dose-escalation study of the p38 alpha MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome** *LEUKEMIA*
Sokol, L., Cripe, L., Kantarjian, H., Sekeres, M. A., Parmar, S., Greenberg, P., Goldberg, S. L., Bhushan, V., Shammo, J., Hohl, R., Verma, A., Garcia-Manero, G., Li, et al
2013; 27 (4): 977-80

- **Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Pang, W. W., Pluvinae, J. V., Price, E. A., Sridhar, K., Arber, D. A., Greenberg, P. L., Schrier, S. L., Park, C. Y., Weissman, I. L.
2013; 110 (8): 3011-3016
- **Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials** *JOURNAL OF CLINICAL ONCOLOGY*
Koontz, M. Z., Horning, S. J., Balise, R., Greenberg, P. L., Rosenberg, S. A., Hoppe, R. T., Advani, R. H.
2013; 31 (5): 592-598
- **A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine** *LEUKEMIA & LYMPHOMA*
Greenberg, P. L., Garcia-Manero, G., Moore, M., Damon, L., Roboz, G., Hu, K., Yang, A. S., Franklin, J.
2013; 54 (2): 321-328
- **Specific plasma autoantibody reactivity in myelodysplastic syndromes** *Scientific Reports*
Mias, G. I., Chen, R., Zhang, Y., Sridhar, K., Sharon, D., Xiao, L., Im, H., Snyder, M. P., Greenberg, P. L.
2013; 3: 3311-3319
- **Reduced rRNA expression and increased rDNA promoter methylation in CD34(+) cells of patients with myelodysplastic syndromes** *BLOOD*
Raval, A., Sridhar, K. J., Patel, S., Turnbull, B. B., Greenberg, P. L., Mitchell, B. S.
2012; 120 (24): 4812-4818
- **Revised International Prognostic Scoring System for Myelodysplastic Syndromes** *BLOOD*
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sole, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, et al
2012; 120 (12): 2454-2465
- **Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow** *LABORATORY INVESTIGATION*
Flores-Figueroa, E., Varma, S., Montgomery, K., Greenberg, P. L., Gratzinger, D.
2012; 92 (9): 1330-1341
- **Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS** *BLOOD*
Barreyro, L., Will, B., Bartholdy, B., Zhou, L., Todorova, T. I., Stanley, R. F., Ben-Neriah, S., Montagna, C., Parekh, S., Pellagatti, A., Boulwood, J., Paietta, E., Ketterling, et al
2012; 120 (6): 1290-1298
- **CHRONICALLY TRANSFUSED MYELOYDYSPLASTIC SYNDROMES (MDS) PATIENTS HAVE SEVERE IRON BURDEN: DEFERASIROX TREATMENT REDUCES IRON OVERLOAD AND IMPROVES LIVER FUNCTION**
Gattermann, N., Greenberg, P., Urabe, A., Habr, D., Kpamegan, E., Porter, J.
FERRATA STORTI FOUNDATION.2012: 138
- **Molecular and genetic features of myelodysplastic syndromes** *INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY*
Greenberg, P. L.
2012; 34 (3): 215-222
- **Efficacy and tolerability of lenalidomide (LEN) in patients (pts) 75 and older versus those younger than 75 with RBC transfusion-dependent low/int-1-risk MDS and del 5q**
Fenaux, P., Guerci-Bresler, A., Muus, P., Sekeres, M. A., Giagounidis, A., Deeg, H., Greenberg, P., Skikne, B., Yu, X., List, A. F.
AMER SOC CLINICAL ONCOLOGY.2012
- **Nano-scale phospho-proteomic analysis to define diagnostic signatures and biomarkers of therapeutic activity in cancer**
Fan, A. C., Banerjee, P., Xu, L., Kong, C., Sabatti, C., Wilhelm, F., Greenberg, P., Felsher, D. W.
AMER ASSOC CANCER RESEARCH.2012
- **Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes** *CELL*
Chen, R., Mias, G. I., Li-Pook-Than, J., Jiang, L., Lam, H. Y., Chen, R., Miriami, E., Karczewski, K. J., Hariharan, M., Dewey, F. E., Cheng, Y., Clark, M. J., Im, et al
2012; 148 (6): 1293-1307

- **New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge** *JOURNAL OF CLINICAL ONCOLOGY*
Schanz, J., Tuechler, H., Sole, F., Mallo, M., Luno, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., Steidl, C., Fonatsch, C., Pfeilstoecker, et al
2012; 30 (8): 820-829
- **Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow** *Lab Investigation*
Flores-Figueroa E, Varma S, Montgomery K, Greenberg P, Gratzinger D
2012; 92: 1330-1341
- **Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na** *LEUKEMIA RESEARCH*
Seetharam, M., Fan, A. C., Tran, M., Xu, L., Renschler, J. P., Felsher, D. W., Sridhar, K., Wilhelm, F., Greenberg, P. L.
2012; 36 (1): 98-103
- **A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib)** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Fan, A. C., Xu, L., Sridhar, K. J., Tran, M., Banerjee, P., Renschler, J. P., Tripuraneni, R., Wilhelm, F., Greenberg, P. L., Felsher, D. W.
AMER SOC HEMATOLOGY.2011: 1626-26
- **A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS**
Koreth, J., Pidala, J., Perez, W. S., Deeg, H., Garcia-Manero, G., Malcovati, L., Cazzola, M., Park, S., Itzykson, R., Ades, L., Fenaux, P., Jaedersten, M., Hellstrom-Lindberg, et al
AMER SOC HEMATOLOGY.2011: 56-57
- **Do Erythropoiesis-Stimulating Agents (ESAs) Affect Survival in Anemic Patients with Myelodysplastic Syndromes (MDS)?**
Davidoff, A. J., Ke, X., Baer, M. R., Smith, S., Zandberg, D., Hendrick, F., Sato, M., Greenberg, P. L., Gore, S. D.
AMER SOC HEMATOLOGY.2011: 1204-5
- **Final Phase I/II Results of Rigosertib (ON 01910.Na) Hematological Effects in Patients with Myelodysplastic Syndrome and Correlation with Overall Survival**
Raza, A., Greenberg, P. L., Olnes, M. J., Silverman, L. R., Wilhelm, F.
AMER SOC HEMATOLOGY.2011: 1633
- **Characterization and prognostic significance of cytogenetically unrelated clones in myelodysplastic syndromes and acute myeloid leukemia**
Schanz, J., Kessels, S., Haferlach, C., Bardi, G., Gourgouveli, E., Slovak, M. L., Johansson, B., Ohyashiki, K., Sole, F., Eclache, Wimzal, F., Pfeilstoecker, M., Noesslinger, T., et al
KARGER.2011: 8
- **Myelodysplastic Syndromes: Dissecting the Heterogeneity** *JOURNAL OF CLINICAL ONCOLOGY*
Greenberg, P. L.
2011; 29 (15): 1937-1938
- **Single-cell network profiling (SCNP) to evaluate the proteomic profiles associated with ON 01910.Na treatment of MDS patients (Pts)**
Cesano, A., Soper, D., Banville, S., Mai Tran, Seetharam, M., Kumar, R., Wilhelm, F., Greenberg, P.
AMER ASSOC CANCER RESEARCH.2011
- **NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.** *Journal of the National Comprehensive Cancer Network*
Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., Foran, J. M., Gaensler, K., Garcia-Manero, G., Gore, S. D., Head, D., Komrokji, R., Maness, et al
2011; 9 (1): 30-56
- **Myelodysplastic Syndromes** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., Foran, J. M., Gaensler, K., Garcia-Manero, G., Gore, S. D., Head, D., Komrokji, R., Maness, et al
2011; 9 (1): 30-56

- **Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes** *LEUKEMIA RESEARCH*
Greenberg, P. L., Koller, C. A., Cabantchik, Z. I., Warsi, G., Glynos, T., Paley, C., Schiffer, C.
2010; 34 (12): 1560-1565
- **Prognostic Impact of Monosomy 7 as a Single Anomaly in Primary MDS - Reclassification From Poor to Intermediate Prognosis**
Schanz, J., Tuechler, H., Sole, F., Mallo, M., Hildebrandt, B., Steidl, C., Fonatsch, C., Pfeilstoecker, M., Noesslinger, T., Valent, P., Giagounidis, A., Luebbert, M., Stauder, et al
AMER SOC HEMATOLOGY.2010: 775-76
- **Overall Survival In Myelodysplastic Syndrome or Acute Myeloid Leukemia Patients Treated with On 01910.Na Correlates with Bone Marrow Blast Response.**
Silverman, L. R., Kaza, A., Sloand, E. M., Greenberg, P. L., Wilhelm, F. E.
AMER SOC HEMATOLOGY.2010: 1629-30
- **Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality?**
Ganster, C., Braulke, F., Shirneshan, K., Sole, F., Mallo, M., Cervera, J., Luno, E., Hildebrandt, B., Steidl, C., Fonatsch, C., Pfeilstoecker, M., Noesslinger, T., Valent, et al
AMER SOC HEMATOLOGY.2010: 1634
- **A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study**
Pebet, T., Sun, Z., Ketterling, R., Hicks, G., Beach, C. L., Greenberg, P. L., Paietta, E., Czader, M., Gabrilove, J., Erba, H. P., Tallman, M. S., Gore, S. D.
AMER SOC HEMATOLOGY.2010: 1636
- **Unrelated Clones In Myelodysplastic Syndromes and Acute Myeloid Leukemia - Characterization and Prognostic Relevance**
Schanz, J., Stephanie, F., Haferlach, C., Bardi, G., Slovak, M. L., Eclache, V., Johansson, B., Ohyashiki, K., Sole, F., Prescher, G., Pfeilstoecker, M., Noesslinger, T., Fonatsth, et al
AMER SOC HEMATOLOGY.2010: 1639
- **Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy** *BLOOD*
Kantarjian, H. M., Giles, F. J., Greenberg, P. L., Paquette, R. L., Wang, E. S., Gabrilove, J. L., Garcia-Manero, G., Hu, K., Franklin, J. L., Berger, D. P.
2010; 116 (17): 3163-3170
- **Loss of the Y Chromosome in MDS: Clonal abnormality or age-related accident?**
Ganster, C., Schanz, J., Braulke, F., Shimeshan, K., Sole, F., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., Steidl, C., Fonatsch, C., Noesslinger, T., Valent, P., Giagounidis, et al
KARGER.2010: 224
- **Unrelated clones in AML/MDS - characterisation and prognostic relevance**
Fischer, S., Haase, D., Haferlach, C., Bardi, G., Slovak, M., Johansson, B., Ohyashiki, K., Sole, F., Eclache, Greenberg, P., LeBeau, M. M., Bennett, J., Prescher, G., et al
KARGER.2010: 37
- **Current therapeutic approaches for patients with myelodysplastic syndromes** *BRITISH JOURNAL OF HAEMATOLOGY*
Greenberg, P. L.
2010; 150 (2): 131-143
- **PROPOSAL OF A NEW, COMPREHENSIVE CYTOGENETIC SCORING SYSTEM FOR PRIMARY MDS**
Schanz, J., Tuechler, H., Sole, F., Mallo, M., Hildebrandt, B., Slovak, M., Ohyashiki, K., Steidl, C., Fonatsch, C., Pfeilstoecker, M., Noesslinger, T., Valent, P., Giagounidis, et al
FERRATA STORTI FOUNDATION.2010: 219
- **PROPOSAL OF A NEW, COMPREHENSIVE CYTOGENETIC SCORING SYSTEM FOR PRIMARY MDS**
Schanz, J., Tuechler, H., Sole, F., Mallo, M., Hildebrandt, B., Slovak, M., Ohyashiki, K., Steidl, C., Fonatsch, C., Pfeilstoecker, M., Noesslinger, T., Valent, P., Giagounidis, et al
FERRATA STORTI FOUNDATION.2010: 219
- **NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes.** *Journal of the National Comprehensive Cancer Network*

- Greenberg, P. L., Rigsby, C. K., Stone, R. M., Deeg, H. J., Gore, S. D., Millenson, M. M., Nimer, S. D., O'Donnell, M. R., Shami, P. J., Kumar, R. 2009; 7: S1-16
- **Relationship of differential gene expression profiles in CD34(+) myelodysplastic syndrome marrow cells to disease subtype and progression** *BLOOD*
Sridhar, K., Ross, D. T., Tibshirani, R., Butte, A. J., Greenberg, P. L.
2009; 114 (23): 4847-4858
 - **Single Cell Network Profiling (SCNP) to Evaluate the Mechanism of Action of ON 01910.Na, A Novel Clinical Trial Stage Compound.**
Soper, D. M., Huang, Y., Wilhelm, F., Cosenza, S. C., Reddy, E., Cesano, A., Greenberg, P. L., Fantl, W. J.
AMER SOC HEMATOLOGY.2009: 1472-73
 - **Safety of Deferasirox (Exjade (R)) in Myelodysplastic Syndromes (MDS) and Non-MDS Patients with Transfusional Iron Overload: A Pooled Analysis Focusing On Renal Function**
Schmid, M., Cappellini, M., Porter, J. B., Greenberg, P. L., Lawniczek, T., Glaser, S., Dong, V., Gattermann, N.
AMER SOC HEMATOLOGY.2009: 702-3
 - **Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine**
Greenberg, P. L., Garcia-Manero, G., Moore, M. R., Damon, L. E., Roboz, G. J., Wei, H., Kantarjian, H., Franklin, J. L.
AMER SOC HEMATOLOGY.2009: 703
 - **Cytogenetic Risk Features in MDS-Update and Present State.**
Schanz, J., Tuechler, H., Sole, F., Mallo, M., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., Steidl, C., Fonatsch, C., Pfeilstoecker, M., Noesslinger, T., Valent, P., Giagounidis, et al
AMER SOC HEMATOLOGY.2009: 1084
 - **Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)** *BLOOD*
Greenberg, P. L., Sun, Z., Miller, K. B., Bennett, J. M., Tallman, M. S., Dewald, G., Paietta, E., van der Jagt, R., Houston, J., Thomas, M. L., Cella, D., Rowe, J. M.
2009; 114 (12): 2393-2400
 - **Change in liver iron concentration (LIC), serum ferritin (SF) and labile plasma iron (LPI) over 1 year of deferasirox (Exjade (R)) therapy in a cohort of patients with MDS**
Greenberg, P. L., Koller, C. A., Glynos, T., Paley, C., Schiffer, C.
PERGAMON-ELSEVIER SCIENCE LTD.2009: S120
 - **A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes** *AMERICAN JOURNAL OF HEMATOLOGY*
Gottlib, J., Lavori, P., Quesada, S., Stein, R. S., Shahnia, S., Greenberg, P. L.
2009; 84 (1): 15-20
 - **NCCN Task Force Report: Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes** *J Nat Comp Cancer Network*
Greenberg, P., Rigsby C, Stone RM, Deeg J, Gore S, Millenson M, Nimer S, O'Donnell M, Shami P, Kumar R
2009; 7 ((Suppl 9): S1-16
 - **Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine**
Kantarjian, H., Giles, F., Greenberg, P., Paquette, R., Wang, E., Gabrilove, J., Garcia-Mancro, G., Gray, J., Hu, K., Franklin, J.
AMER SOC HEMATOLOGY.2008: 89-90
 - **Myelodysplastic syndromes.** *Journal of the National Comprehensive Cancer Network*
Greenberg, P. L., Attar, E., Battiwalla, M., Bennett, J. M., Bloomfield, C. D., DeCastro, C. M., Deeg, H. J., Erba, H. P., Foran, J. M., Garcia-Manero, G., Gore, S. D., Head, D., Maness, et al
2008; 6 (9): 902-926
 - **The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.** *Journal of the National Comprehensive Cancer Network*
Greenberg, P. L., Cosler, L. E., Ferro, S. A., Lyman, G. H.
2008; 6 (9): 942-953
 - **Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy** *JOURNAL OF CLINICAL ONCOLOGY*

- Sloand, E. M., Wu, C. O., Greenberg, P., Young, N., Barrett, J.
2008; 26 (15): 2505-2511
- **A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia** *BLOOD*
Raponi, M., Lancet, J. E., Fan, H., Dossey, L., Lee, G., Gojo, I., Feldman, E. J., Gotlib, J., Morris, L. E., Greenberg, P. L., Wright, J. J., Harousseau, J., Loewenberg, et al
2008; 111 (5): 2589-2596
 - **Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study** *EUROPEAN JOURNAL OF HAEMATOLOGY*
Porter, J., Galanello, R., Saglio, G., Neufeld, E. J., Vichinsky, E., Cappellini, M. D., Olivieri, N., Piga, A., Cunningham, M. J., Soulieres, D., Gattermann, N., Tchernia, G., Maertens, et al
2008; 80 (2): 168-176
 - **Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience** *BLOOD*
Park, S., Grabar, S., Kelaidi, C., Beyne-Rauzy, O., Picard, F., Bardet, V., Coiteux, V., Leroux, G., Lepelley, P., Daniel, M., Cheze, S., Mahe, B., Ferrant, et al
2008; 111 (2): 574-582
 - **International MDS Risk Analysis Workshop (IMRAW)/IPSS Re-analyzed: Impact of cytopenias on clinical outcomes in Myelodysplastic Syndrome** *Am J Hematology*
Kao, J. M., McMillan, A., Greenberg, P. L.
2008; 83: 765-770
 - **Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q** *48th Annual Meeting of the American-Society-of-Hematology*
Raza, A., Reeves, J. A., Feldman, E. J., Dewald, G. W., Bennett, J. M., Deeg, J., Dreisbach, L., Schiffer, C. A., Stone, R. M., Greenberg, P. L., Curtin, P. T., Klimek, V. M., Shammo, et al
AMER SOC HEMATOLOGY.2008: 86-93
 - **Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF** *Blood*
Park S, Grabar S, Kelaidi C, Greenberg P, et al.
2008; 111: 574-582
 - **Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-year prospective study.** *Eur J Haematol*
Porter J, Galanello R, Saglio S, Greenberg P, et al
2008; 80: 168-176
 - **Phase II Study of Lenalidomide in Transfusion-Dependent, Low and Intermediate-1-Risk Myelodysplastic Syndromes with Normal and Abnormal Karyotypes Other than Deletion 5q.** *Blood*
Raza A, Reeves JE, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, et al
2008; 111: 86-93
 - **A two-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia**
Raponi, M., Lancet, J. E., Fan, H., Dossey, L., Lee, G., Gojo, I., Feldman, E. J., Gotlib, J., Morris, L. E., Greenberg, P. L., Wright, J. J., Harousseau, J., Lowenberg, et al
AMER SOC HEMATOLOGY.2007: 433A
 - **Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference** *LEUKEMIA RESEARCH*
Valent, P., Horny, H., Bennett, J. M., Fonatsch, C., Germing, U., Greenberg, P., Haferlach, T., Haase, D., Kolb, H., Krieger, O., Loken, M., van de Loosdrecht, A., Ogata, et al
2007; 31 (6): 727-736
 - **Proposed minimal diagnostic criteria for myelodysplastic syndromes**
Valent, P., Horny, H., Fonatsch, C., Germing, U., Greenberg, P., Haferlach, T., Haase, D., Kolb, H., Krieger, O., Loken, M., Van de Loosdrecht, A., Ogata, K., Orfao, et al
FERRATA STORTI FOUNDATION.2007: 80
 - **Chronic myelogenous leukemia.** *Journal of the National Comprehensive Cancer Network*

- O'Brien, S., Berman, E., Bhalla, K., Copelan, E. A., Devetten, M. P., Emanuel, P. D., Erba, H. P., Greenberg, P. L., Moore, J. O., Przepiora, D., Radich, J. P., Schilder, R. J., Shami, et al
2007; 5 (5): 474-496
- **A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia** *BLOOD*
Lancet, J. E., Gojo, I., Gotlib, J., Feldman, E. J., Greer, J., Liesveld, J. L., Bruzek, L. M., Morris, L., Park, Y., Adjei, A. A., Kaufmann, S. H., Garrett-Mayer, E., Greenberg, et al
2007; 109 (4): 1387-1394
 - **Myelodysplastic Syndromes: Impact of recently analyzed variables for modifying current classification methods** *Clinical Leukemia*
Kao JM, Greenberg PL
2007; 1: 172-182
 - **Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus Statements and Report from a Working Conference** *Leukemia Research*
Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et al
2007; 31: 727-736
 - **Phase I/II, randomized, MultiCenter, dose-ascension study of the p38MAPK inhibitor scio469 in patients with myelodysplastic syndrome (MDS).** *48th Annual Meeting of the American-Society-of-Hematology*
Sokol, L., Cripe, L., Kantarjian, H., Sekeres, M. A., Parmar, S., Greenberg, P., Goldberg, S., Bhushan, V., Shammo, J., Hohl, R., Li, Y., Lowe, A., Zhu, et al
AMER SOC HEMATOLOGY.2006: 751A-751A
 - **Long term clinical benefit of lenalidomide (Revlimid) treatment in patients with myelodysplastic syndrome without del 5q cytogenetic abnormalities.**
Raza, A., Reeves, J. E., Feldman, E. J., Deeg, H., Dreisbach, L., Schiffer, C. A., Shammo, J. M., Klimek, V. M., Greenberg, P. L., Bennett, J. M., DeWald, G. W., Zeldis, J. B., Wride, et al
AMER SOC HEMATOLOGY.2006: 78A
 - **Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion** *NEW ENGLAND JOURNAL OF MEDICINE*
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., Reeder, C., Wride, K., Patin, et al
2006; 355 (14): 1456-1465
 - **Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia** *BLOOD*
Cheson, B. D., Greenberg, P. L., Bennett, J. M., Lowenberg, B., Wijermans, P. W., Nimer, S. D., Pinto, A., Beran, M., de Witte, T. M., Stone, R. M., Mittelman, M., Sanz, G. F., Gore, et al
2006; 108 (2): 419-425
 - **Hematologic and cytogenetic response to lenalidomide in myelodysplastic syndrome with chromosome 5q deletion.** *New Eng J Med*
List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, et al
2006; 355: 1456-1465
 - **Myelodysplastic syndromes clinical practice guidelines in oncology.** *Journal of the National Comprehensive Cancer Network*
Greenberg, P. L., Baer, M. R., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., Devetten, M. P., Emanuel, P. D., Erba, H. P., Estey, E., Foran, J., Gore, S. D., Millenson, et al
2006; 4 (1): 58-77
 - **A phase II study of the farnesyltransferase inhibitor tipifarnib in elderly patients with previously untreated poor-risk acute myeloid leukemia** *Blood*
Lancet J, Gojo I, Gotlib J, Greenberg PL, et al
2006; 108: 1387-1394
 - **Myelodysplastic Syndromes: Clinical and Biological Advances** *Cambridge University Press, Cambridge, England*
Greenberg, P. L.
2006
 - **Myelodysplastic syndromes: iron overload consequences and current chelating therapies.** *Journal of the National Comprehensive Cancer Network*
Greenberg, P. L.

2006; 4 (1): 91-96

- **Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.** *Blood*
Cheson BD, Greenberg PL, Bennett JM, et al
2006; 108: 419-425
- **Deferasirox (Exjade (R), ICL670) demonstrates dose-related effects on body iron levels related to transfusional iron intake in transfusion-dependent anemia**
Greenberg, P., Dine, G., Ganser, A., Verhoef, G., DeBusscher, L., Quarta, G., Zachee, P., Alimena, G., Jeng, M., Tchernia, G., Gathmann, Alberti, D., Rabault, B.
AMER SOC HEMATOLOGY.2005: 757A
- **Management of patients with higher risk myelodysplastic syndromes** *CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY*
Fukumoto, J. S., Greenberg, P. L.
2005; 56 (2): 179-192
- **Chronic myelogenous leukemia.** *Journal of the National Comprehensive Cancer Network*
O'Brien, S., Berman, E., Bhalha, K., Copelan, E. A., Devetten, M. P., Emanuel, P. D., Erba, H. P., Greenberg, P. L., Moore, J. O., Przepiorka, D., Radich, J. P., Schilder, R. J., Shami, et al
2005; 3 (6): 732-755
- **Phase II trial of darbepoetin alfa in myelodysplastic syndrome (MDS): Preliminary efficacy, safety, and in vitro results.**
Gotlib, J., Quesada, S., Bhamidipati, J., Chaudry, K., Sridhar, K., Dugan, K., Stein, R., Tupper, G., Greenberg, P. L.
AMER SOC HEMATOLOGY.2004: 267B-268B
- **A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome** *BLOOD*
Cutler, C. S., Lee, S. J., Greenberg, P., Deeg, H. J., Perez, W. S., Anasetti, C., Bolwell, B. J., Cairo, M. S., Gale, R. P., Klein, J. P., Lazarus, H. M., Liesveld, J. L., McCarthy, et al
2004; 104 (2): 579-585
- **Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)** *JOURNAL OF CLINICAL ONCOLOGY*
Greenberg, P. L., Lee, S. J., Advani, R., Tallman, M. S., Sikic, B. I., Letendre, L., Dugan, K., Lum, B., Chin, D. L., Dewald, G., Paietta, E., Bennett, J. M., Rowe, et al
2004; 22 (6): 1078-1086
- **A Decision Analysis of Allogeneic Bone Marrow Transplantation for the Myelodysplastic Syndromes: Delayed Transplantation for Low Risk Myelodysplasia is Associated with Improved Outcome** *Blood*
Cutler C, Lee SJ, Greenberg P, et al
2004; 104: 579-585
- **Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study** *LEUKEMIA RESEARCH*
Cherry, A. M., Brockman, S. R., Paternoster, S. F., Hicks, G. A., Neuberger, D., Higgins, R. R., Bennett, J. M., Greenberg, P. L., Miller, K., Tallman, M. S., Rowe, J., DeWald, G. W.
2003; 27 (12): 1085-1090
- **Phase II study of Bevacizumab (anti-VEGF humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS): Preliminary results** *45th Annual Meeting and Exhibition of the American-Society-of-Hematology*
Gotlib, J., Jamieson, C. H., List, A., Cortes, J., Albitar, M., Sridhar, K., Dugan, K., Quesada, S., Diaz, G., Pate, O., Novotny, W., Chen, H., Greenberg, et al
AMER SOC HEMATOLOGY.2003: 425A-425A
- **Tipifarnib (ZARNESTRA (TM)) and imatinib (GLEEVEC (TM)) combination therapy in patients with advanced chronic myelogenous leukemia (CML): Preliminary results of a phase I study.**
Gotlib, J., Mauro, M., O'Dwyer, M. E., Fechter, L., Dugan, K., Kuyl, J., Yekrang, A., Mori, M., Rackoff, W., Coutre, S., Druker, B., Greenberg, P. L.
AMER SOC HEMATOLOGY.2003: 909A-910A
- **Phase I/II study of tipifarnib (ZARNESTRA (TM)), farnesyltransferase inhibitor [FTI] R115777) in patients with myeloproliferative disorders (MPDs): Interim results.**

- Gotlib, J., Loh, M., Lancet, J. E., Vattikuti, S., Quesada, S., Dugan, K., Katamneni, U., Sridhar, K., Wright, J., Thibault, A., Rybak, M. E., Shannon, K. M., Greenberg, et al
AMER SOC HEMATOLOGY.2003: 921A
- **Leukemic cell resistance: targeting needed beyond MDR-1** *BLOOD*
Greenberg, P.
2003; 102 (4): 1149
 - **Novel biospecific agents for the treatment of myelodysplastic syndromes.** *J Nat Comprehensive Cancer Network*
Gotlib J, Greenberg P
2003; 1: 473-480
 - **Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study** *LEUKEMIA*
Deeg, H. J., Gotlib, J., Beckham, C., Dugan, K., Holmberg, L., Schubert, M., Appelbaum, F., Greenberg, P.
2002; 16 (2): 162-164
 - **Myelodysplastic syndromes.** *Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program*
Greenberg, P. L., Young, N. S., Gattermann, N.
2002: 136-161
 - **Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines** *ANNALS OF THE RHEUMATIC DISEASES*
Greenberg, P.
2001; 60: III41-III42
 - **Classifying chronic myelomonocytic leukemia - In Reply** *JOURNAL OF CLINICAL ONCOLOGY*
Greenberg, P., Anderson, J., Estey, E., Fenaux, P., Hamblin, T., Hellstrom-Lindberg, E., List, A., Ohyashiki, K., Sanz, G., Zanz, M.
2001; 19 (17): 3791-92
 - **Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes** *LANCET*
Greenberg, P.
2001; 357 (9262): 1059-1060
 - **Report of an international working group to standardize response criteria for myelodysplastic syndromes** *BLOOD*
Cheson, B. D., Bennett, J. M., Kantarjian, H., Pinto, A., Schiffer, C. A., Nimer, S. D., Lowenberg, B., Beran, M., de Witte, T. M., Stone, R. M., Mittelman, M., Sanz, G. F., Wijermans, et al
2000; 96 (12): 3671-74
 - **Soluble TNF receptor fusion protein (TNFR : Fc; Enbrel) in the treatment of patients with myelodysplastic syndrome (MDS).**
Deeg, H. J., Gotlib, J., Beckham, C., Dugan, K., Appelbaum, F., Greenberg, P.
AMER SOC HEMATOLOGY.2000: 146A
 - **NCCN Practice Guidelines for chronic myelogenous leukemia** *ONCOLOGY-NEW YORK*
Talpaz, M., Berman, E., Clift, R. A., Copelan, E. A., Emanuel, P. D., Erba, H. P., Glenn, M. J., Greenberg, P. L., Jones, R. J., O'Brien, S., Saba, H. I., Schilder, R., Snyder, et al
2000; 14 (11A): 229-240
 - **Problematic WHO reclassification of myelodysplastic syndromes** *JOURNAL OF CLINICAL ONCOLOGY*
Greenberg, P., Anderson, J., de Witte, T., Estey, E., Fenaux, P., Gupta, P., Hamblin, T., Hellstrom-Lindberg, E., List, A., Mufti, G., Neuwirtova, R., Ohyashiki, K., Oscier, et al
2000; 18 (19): 3447-49
 - **The Myelodysplastic Syndromes .** *HEMATOLOGY: BASIC PRINCIPLES AND PRACTICE 3rd Ed., Hoffman R, Benz E, Shattil S, Furie B, Cohen H, Silberstein L, McGlave P, Eds. Churchill Livingstone, NY,*
Greenberg, P.
2000: 1106-1129
 - **Quality of life in individuals with myelodysplastic syndromes (MDS): A descriptive study.**
Thomas, M. L., Zhang, J., Greenberg, P. L.
AMER SOC HEMATOLOGY.1999: 662A

- **Phase II study of amifostine in patients with myelodysplastic syndromes (MDS).**
List, A. F., Holmes, H., Greenberg, P. L., Bennett, J. M., Oster, W.
AMER SOC HEMATOLOGY.1999: 305A
- **Prognostic scoring systems for risk assessment in myelodysplastic syndromes.** *Forum (Genoa, Italy)*
Greenberg, P. L., Sanz, G. F., Sanz, M. A.
1999; 9 (1): 17-31
- **Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment** *LEUKEMIA RESEARCH*
Greenberg, P. L.
1998; 22 (12): 1123-1136
- **Amifostine in combination with cytokines stimulates in vitro hemopoiesis in myelodysplastic syndromes (MDS).**
Rajapaksa, R., Bhatia, S., Swarnakar, A., Kodali, U., Greenberg, P. L.
W B SAUNDERS CO.1998: 160B
- **Phase II study of amifostine in patients with myelodysplastic syndromes (MDS): Impact on hematopoiesis.**
List, A. F., Holmes, H., Vempaty, H., Greenberg, P. L., Bennett, J. M.
W B SAUNDERS CO.1998: 714A
- **Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression** *36th Annual Meeting of the American-Society-of-Hematology*
Davis, R. E., Greenberg, P. L.
PERGAMON-ELSEVIER SCIENCE LTD.1998: 767-77
- **Risk factors and their relationship to prognosis in myelodysplastic syndromes** *LEUKEMIA RESEARCH*
Greenberg, P. L.
1998; 22: S3-S6
- **Prognostic factors and scoring systems in myelodysplastic syndromes** *HAEMATOLOGICA*
Sanz, G. F., Sanz, M. A., Greenberg, P. L.
1998; 83 (4): 358-368
- **NCCN Practice Guidelines for Myelodysplastic Syndromes** *Oncology*
Greenberg PL, Bishop M, Deeg J, Erba H, Gore S, Nimer S, ODonnell M, Tallman M, Bennett J, Estey E, Stone R
1998; 12 (11A): 53-80
- **International prognostic scoring system and other prognostic systems for myelodysplastic syndromes - Response** *BLOOD*
Greenberg, P., Cox, C., Bennett, J.
1997; 90 (10): 4233-34
- **Treatment of poor prognosis AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC).**
Advani, R., Saba, H. I., Tallman, M., Rowe, J. M., Wiernik, P. H., Ramek, J., Dugan, K., Lum, B., Villena, J., Sikic, B. I., Davis, E., Paietta, E., Litchman, et al
W B SAUNDERS CO.1997: 2260
- **Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model** *BRITISH JOURNAL OF HAEMATOLOGY*
HELLSTROMLINDBERG, E., Negrin, R., Stein, R., Krantz, S., Lindberg, G., Vardiman, J., Ost, A., Greenberg, P.
1997; 99 (2): 344-351
- **International scoring system for evaluating prognosis in myelodysplastic syndromes** *BLOOD*
Greenberg, P., Cox, C., LEBEAU, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, et al
1997; 89 (6): 2079-2088
- **Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells** *BLOOD*
Rajapaksa, R., Ginzton, N., Rott, L. S., Greenberg, P. L.
1996; 88 (11): 4275-4287

- **GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation** *BONE MARROW TRANSPLANTATION*
Greenberg, P., Advani, R., Keating, A., Gulati, S. C., Nimer, S., Champlin, R., Karanes, C., Gorin, N. C., Powles, R. L., Smith, A., Lamborn, K., Cuffie, C.
1996; 18 (6): 1057-1064
- **Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy** *BLOOD*
Negrin, R. S., Stein, R., Doherty, K., Cornwell, J., Vardiman, J., Krantz, S., Greenberg, P. L.
1996; 87 (10): 4076-4081
- **Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes** *SEMINARS IN HEMATOLOGY*
Greenberg, P. L.
1996; 33 (2): 163-175
- **Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human G-CSF plus erythropoietin: Evidence for in vivo synergy** *Blood*
Negrin RS, Stein R, Doherty K, Cromwell J, Vardiman J, Krantz S, Greenberg PL
1996; 87: 4076-4081
- **Efficacy of G-CSF and EPO on the anaemia in patients with myelodysplastic syndromes (MDS).**
HellstromLindberg, E., Negrin, R., Stein, R., Krantz, S., Vardiman, J., Ost, A., Lindberg, G., Greenberg, P.
W B SAUNDERS CO.1995: 1340
- **International workshop consensus risk analysis system for myelodysplastic syndromes (MDS).**
Greenberg, P., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G., Bennett, et al
W B SAUNDERS CO.1995: 1065
- **ENRICHMENT OF BONE-MARROW AND BLOOD PROGENITOR (CD34(+)) CELLS BY DENSITY GRADIENTS WITH SUFFICIENT YIELDS FOR TRANSPLANTATION** *EXPERIMENTAL HEMATOLOGY*
Schriber, J. R., DEJBAKHSHJONES, S., KUSNIERZGLAZ, C. R., Ginzton, N., Still, B., Negrin, R. S., Greenberg, P., Strober, S.
1995; 23 (9): 1024-1029
- **MODULATION OF APOPTOSIS IN HUMAN MYELOID LEUKEMIC-CELLS BY GM-CSF** *EXPERIMENTAL HEMATOLOGY*
Han, J. H., Gileadi, C., Rajapaksa, R., Kosek, J., Greenberg, P. L.
1995; 23 (3): 265-272
- **THE ROLE OF HEMATOPOIETIC GROWTH-FACTORS IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES** *International Symposium on Current Problems of Childhood Panmyelopathies - Focus on Myelodysplastic Syndrome*
Greenberg, P.
MINISTERSTVO ZDRAVOOKHRANENIYA.1995: 12-13
- **EFFECTS OF GRANULOCYTE-COLONY-STIMULATING FACTOR THERAPY ON IN-VITRO HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES** *LEUKEMIA*
Nagler, A., MacKichan, M. L., Negrin, R. S., Donlon, T., Greenberg, P. L.
1995; 9 (1): 30-39
- **BCL-2 EXPRESSION BY MYELOID PRECURSORS IN MYELODYSPLASTIC SYNDROMES (MDS) - IMMUNOSTAINING OF BONE-MARROW (BM) BIOPSIES**
DAVIS, R. E., GREENBERG, P. L.
W B SAUNDERS CO.1994: A314
- **ONCOPROTEIN EXPRESSION AND APOPTOSIS IN MYELODYSPLASTIC SYNDROME (MDS) MARROW-CELLS**
GREENBERG, P. L., GINZTON, N., RAJAPAKSA, R.
W B SAUNDERS CO.1994: A54
- **EXPRESSION OF EVI1 IN MYELODYSPLASTIC SYNDROMES AND OTHER HEMATOLOGIC MALIGNANCIES WITHOUT 3Q26 TRANSLOCATIONS** *BLOOD*
Russell, M., List, A., Greenberg, P., Woodward, S., Glinsmann, B., Parganas, E., Ihle, J., Taettle, R.
1994; 84 (4): 1243-1248

- **GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) PLUS ERYTHROPOIETIN (EPO) FOR THE MAINTENANCE TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES (MDS)**
NEGRIN, R. S., STEIN, R., DOHERTY, K., CORNWELL, J., VARDIMAN, J., KRANTZ, S., GREENBERG, P. L.
CARDEN JENNINGS PUBL CO LTD.1994: 703
- **MUTATIONS IN THE RAS PROTOONCOGENES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES** *LEUKEMIA*
Neubauer, A., Greenberg, P., Negrin, R., Ginzton, N., Liu, E.
1994; 8 (4): 638-641
- **PHASE-III RANDOMIZED MULTICENTER TRIAL OF G-CSF VS OBSERVATION FOR MYELODYSPLASTIC SYNDROMES (MDS)**
Greenberg, P., Taylor, K., Larson, R., Koeffler, P., Negrin, R., Saba, H., Ganser, A., Jakubowski, A., Gabrilove, J., Mufti, G., Cruz, J., Hammond, W., Broudy, et al
AMER SOC HEMATOLOGY.1993: A196–A196
- **HIGH-INCIDENCE OF POLYCLONAL GRANULOCYTOPOIESIS IN MYELODYSPLASTIC SYNDROMES (MDS)**
BUSQUE, L., KOHLER, S., DEHART, D., SAXENA, R., BERNSTEIN, S., STONE, R., GREENBERG, P., GILLILAND, D. G.
W B SAUNDERS CO.1993: A196
- **THE PROGNOSTIC-SIGNIFICANCE OF CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES (MDS) FOLLOWING G-CSF**
LEBEAU, M., TAYLOR, K., LARSON, R., KOEFFLER, P., NEGRIN, R., SABA, H., GANSER, A., JAKUBOWSKI, A., GABRILOVE, J., MUFTI, G. J., CRUZ, J., LANGLEY, G., VARDIMAN, et al
AMER SOC HEMATOLOGY.1993: A375
- **CLONALITY ANALYSIS IN MYELODYSPLASIA (MDS) PATIENTS TREATED WITH G-CSF**
KOHLER, S., BUSQUE, L., DEHART, D., LEBEAU, M., NEGRIN, R., GANSER, A., GREENBERG, P., GILLILAND, D. G.
W B SAUNDERS CO.1993: A376
- **TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN COMBINATION WITH ERYTHROPOIETIN** *BLOOD*
Negrin, R. S., Stein, R., Vardiman, J., Doherty, K., Cornwell, J., Krantz, S., Greenberg, P. L.
1993; 82 (3): 737-743
- **T-CELL SUBSETS AND SUPPRESSOR CELLS IN HUMAN BONE-MARROW** *BLOOD*
SCHMIDTWOLF, I. G., DEJBAKHSHJONES, S., Ginzton, N., Greenberg, P., Strober, S.
1992; 80 (12): 3242-3250
- **GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) PLUS ERYTHROPOIETIN (EPO) TREATMENT OF MYELODYSPLASTIC SYNDROMES**
NEGRIN, R. S., DOHERTY, K., STEIN, R., VARDIMAN, J., KRANTZ, S., GREENBERG, P. L.
CARDEN JENNINGS PUBL CO LTD.1992: 745
- **INVITRO-INVIVO CORRELATIONS OF ERYTHROID RESPONSES TO G-CSF PLUS ERYTHROPOIETIN (EPO) IN MYELODYSPLASTIC SYNDROMES (MDS)**
GREENBERG, P. L., NEGRIN, R. S., GINZTON, N.
CARDEN JENNINGS PUBL CO LTD.1992: 733
- **INVITRO MARROW CULTURE STUDIES IN THE MYELODYSPLASTIC SYNDROMES** *SEMINARS IN ONCOLOGY*
Greenberg, P. L.
1992; 19 (1): 34-46
- **TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH HEMATOPOIETIC GROWTH-FACTORS** *SEMINARS IN ONCOLOGY*
Greenberg, P. L.
1992; 19 (1): 106-114
- **Programmed cell death (apoptosis) as a mechanism for regulating haematopoietic cell population size** *Focus on Growth Factors*
Greenberg, P. L.
1992; 3 (2): 1-3
- **CLINICAL USE OF MYELOID COLONY STIMULATING FACTORS (CSFS) IN MYELODYSPLASTIC SYNDROMES (MDS)**
GREENBERG, P. L.

CARDEN JENNINGS PUBL CO LTD.1991: 461

- **TREATMENT OF MYELODYSPLASTIC SYNDROMES** *BLOOD REVIEWS*
Greenberg, P. L.
1991; 5 (1): 42-50
- **EFFECTS OF INSULIN-LIKE GROWTH-FACTORS ON HEMATOPOIESIS** *BLOOD CELLS*
Greenberg, P. L.
1991; 17 (2): 344-346
- **Granulocyte-monocyte and Granulocyte-Colony Stimulating Factors in Myelodysplastic Syndromes.** *Leukemia & lymphoma*
Nagler, A., Greenberg, P. L.
1991; 5 (4): 219-30
- **GRANULOCYTE-MONOCYTE AND GRANULOCYTE-COLONY STIMULATING FACTORS IN MYELODYSPLASTIC SYNDROMES** *LEUKEMIA & LYMPHOMA*
Nagler, A., Greenberg, P. L.
1991; 5 (4): 219-230
- **FUNCTIONAL INTERACTIONS BETWEEN COLONY-STIMULATING FACTORS AND THE INSULIN FAMILY HORMONES FOR HUMAN MYELOID LEUKEMIC-CELLS** *CANCER RESEARCH*
Oksenberg, D., DIECKMANN, B. S., Greenberg, P. L.
1990; 50 (20): 6471-6477
- **IMPACT OF MARROW CYTOGENETICS AND MORPHOLOGY ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES - COMPARISON BETWEEN RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (CSF) AND GRANULOCYTE-MONOCYTE CSF** *BLOOD*
Nagler, A., Binet, C., MacKichan, M. L., Negrin, R., Bangs, C., Donlon, T., Greenberg, P.
1990; 76 (7): 1299-1307
- **EFFECTS OF CSFS IN PRELEUKEMIA** *3RD INTERNATIONAL SYMP ON MINIMAL RESIDUAL DISEASE IN ACUTE LEUKEMIA*
Greenberg, P. L., Negrin, R., Nagler, A.
STOCKTON PRESS.1990: 121-126
- **MAINTENANCE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR** *BLOOD*
Negrin, R. S., HAEUBER, D. H., Nagler, A., Kobayashi, Y., Sklar, J., Donlon, T., Vincent, M., Greenberg, P. L.
1990; 76 (1): 36-43
- **BONE-MARROW CELL MODULATION AND INHIBITION OF MYELOPOIESIS BY LARGE GRANULAR LYMPHOCYTES AND NATURAL-KILLER-CELLS** *INTERNATIONAL JOURNAL OF CELL CLONING*
Nagler, A., Greenberg, P. L.
1990; 8 (3): 171-183
- **EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND GRANULOCYTE-MONOCYTE COLONY STIMULATING FACTOR ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES** *LEUKEMIA*
Nagler, A., Ginzton, N., Negrin, R., Bang, D., Donlon, T., Greenberg, P.
1990; 4 (3): 193-202
- **HEMATOPOIETIC PROGENITOR-CELL EXPRESSION OF THE H-CAM (CD44) HOMING-ASSOCIATED ADHESION MOLECULE** *BLOOD*
LEWINSOHN, D. M., Nagler, A., Ginzton, N., Greenberg, P., BUTCHER, E. C.
1990; 75 (3): 589-595
- **EFFECTS OF PROLONGED TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR** *2ND INTERNATIONAL CONF ON BLOOD CELL GROWTH FACTORS : THEIR BIOLOGY AND CLINICAL APPLICATIONS*
Greenberg, P., Negrin, R., Nagler, A., Vincent, M., Donlon, T.
ALPHAMED PRESS.1990: 293-302
- **TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR - CLINICAL AND MARROW HEMATOPOIETIC RESPONSES** *SYMP ON HEMATOPOIESIS*
Greenberg, P., Negrin, R., Nagler, A., Souza, L.

WILEY-LISS, INC.1990: 229-236

- **THE NATURE AND EVOLVING TREATMENT OF MYELOYDYSPLASTIC SYNDROMES** *WESTERN JOURNAL OF MEDICINE*
GREENBERG, P.
1989; 151 (2): 194-96
- **TREATMENT OF MYELOYDYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR - A PHASE I-II TRIAL** *ANNALS OF INTERNAL MEDICINE*
Negrin, R. S., HAEUBER, D. H., Nagler, A., Olds, L. C., Donlon, T., SOUZA, L. M., Greenberg, P. L.
1989; 110 (12): 976-984
- **THE EFFECTS OF RECOMBINANT INTERLEUKIN-2-ACTIVATED NATURAL-KILLER CELLS ON AUTOLOGOUS PERIPHERAL-BLOOD HEMATOPOIETIC PROGENITORS** *JOURNAL OF EXPERIMENTAL MEDICINE*
Nagler, A., Greenberg, P. L., Lanier, L. L., Phillips, J. H.
1988; 168 (1): 47-54
- **TREATMENT OF MYELOYDYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR**
NEGRIN, R. S., HAEUBER, D. H., NAGLER, A., SOUZA, L. M., GREENBERG, P. L.
CARDEN JENNINGS PUBL CO LTD.1988: 519
- **SELECTIVE GENERATION OF ERYTHROID BURST PROMOTING ACTIVITY BY RECOMBINANT INTERLEUKIN-2 STIMULATED HUMAN LYMPHOCYTES-T AND NATURAL-KILLER CELLS** *BLOOD*
Skettino, S., Phillips, J., Lanier, L., Nagler, A., Greenberg, P.
1988; 71 (4): 907-914
- **RECEPTOR-BINDING AND MITOGENIC EFFECTS OF INSULIN AND INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II FOR HUMAN MYELOID LEUKEMIC-CELLS** *JOURNAL OF CELLULAR PHYSIOLOGY*
PEPE, M. G., Ginzton, N. H., Lee, P. D., Hintz, R. L., Greenberg, P. L.
1987; 133 (2): 219-227
- **BIOLOGIC NATURE OF THE MYELOYDYSPLASTIC SYNDROMES** *ACTA HAEMATOLOGICA*
Greenberg, P. L.
1987; 78: 94-99
- **BIOLOGIC ABNORMALITIES IN THE MYELOYDYSPLASTIC SYNDROMES AND MYELOPROLIFERATIVE DISORDERS** *ACTA HAEMATOLOGICA JAPONICA*
Greenberg, P. L.
1986; 49 (8): 1509-1527
- **INVITRO CULTURE TECHNIQUES DEFINING BIOLOGICAL ABNORMALITIES IN THE MYELOYDYSPLASTIC SYNDROMES AND MYELOPROLIFERATIVE DISORDERS** *CLINICS IN HAEMATOLOGY*
GREENBERG, P. L.
1986; 15 (4): 973-93
- **CHARACTERIZATION OF THE INVITRO STROMAL MICROENVIRONMENT OF HUMAN-BONE MARROW** *INTERNATIONAL JOURNAL OF CELL CLONING*
Strobel, E. S., GAY, R. E., Greenberg, P. L.
1986; 4 (5): 341-356
- **13-CIS RETINOIC ACID TREATMENT FOR MYELOYDYSPLASTIC SYNDROMES** *JOURNAL OF CLINICAL ONCOLOGY*
Picozzi, V. J., SWANSON, G. F., Morgan, R., Hecht, F., Greenberg, P. L.
1986; 4 (4): 589-595
- **ABNORMAL INVITRO CLONAL GROWTH-PATTERNS IN THE MYELOYDYSPLASTIC SYNDROMES AND OTHER HEMATOLOGIC MALIGNANCIES - RESPONSES TO RETINOIC ACID AND VITAMIN-D** *ACTA HAEMATOLOGICA JAPONICA*
Greenberg, P.
1986; 49 (2): 181-181
- **RESPONSES OF HEMATOPOIETIC PRECURSORS TO 13-CIS RETINOIC ACID AND 1,25 DIHYDROXYVITAMIN-D3 IN THE MYELOYDYSPLASTIC SYNDROMES** *BLOOD*
Swanson, G., Picozzi, V., Morgan, R., Hecht, F., Greenberg, P.

1986; 67 (4): 1154-1161

- **CORRELATIVE PATTERNS OF LEUKOCYTE COUNTS AT PRESENTATION AND RELAPSE IN ACUTE MYELOGENOUS LEUKEMIA** *ACTA HAEMATOLOGICA*
Schwartz, R. S., MacKintosh, F. R., Greenberg, P. L.
1986; 75 (2): 79-82
- **HUMAN SPLEEN-CELL GENERATION OF FACTORS STIMULATING HUMAN PLURIPOTENT STEM-CELL, ERYTHROID, AND MYELOID PROGENITOR-CELL GROWTH** *BLOOD*
Fabian, I., Douer, D., Levitt, L., Kletter, Y., Greenberg, P. L.
1985; 65 (4): 990-996
- **IMMUNOLOGICAL SELECTION OF HEMATOPOIETIC PRECURSOR CELLS UTILIZING ANTIBODY-MEDIATED PLATE BINDING (PANNING)** *BLOOD*
Greenberg, P. L., Baker, S., Link, M., Minowada, J.
1985; 65 (1): 190-197
- **LITHIUM TREATMENT IN ADULTS WITH ACUTE MYELOID-LEUKEMIA RECEIVING CHEMOTHERAPY** *MEDICAL AND PEDIATRIC ONCOLOGY*
Horns, R. C., Schrier, S. L., Greenberg, P. L.
1984; 12 (3): 169-172
- **GRANULOCYTE DIFFERENTIATION FACTOR PRODUCTION BY HUMAN MARROW AND BLOOD-CELLS**
GREENBERG, P. L., BAKER, S. J., FOK, W. Y., FOUNG, S. K., ENGLEMAN, E. G.
CARDEN JENNINGS PUBL CO LTD.1984: 370
- **MULTIVARIATE-ANALYSIS OF FACTORS ASSOCIATED WITH OUTCOME OF TREATMENT FOR ADULTS WITH ACUTE MYELOGENOUS LEUKEMIA** *CANCER*
Schwartz, R. S., MacKintosh, F. R., Halpern, J., Schrier, S. L., Greenberg, P. L.
1984; 54 (8): 1672-1681
- **MULTIVARIATE-ANALYSIS OF FACTORS ASSOCIATED WITH INVASIVE FUNGAL DISEASE DURING REMISSION INDUCTION THERAPY FOR ACUTE MYELOGENOUS LEUKEMIA** *CANCER*
Schwartz, R. S., MacKintosh, F. R., Schrier, S. L., Greenberg, P. L.
1984; 53 (3): 411-419
- **MURINE GRANULOPOIESIS AFTER FRACTIONATED TOTAL LYMPHOID IRRADIATION AND ALLOGENEIC BONE-MARROW TRANSPLANTATION** *EXPERIMENTAL HEMATOLOGY*
Feiner, R. H., Strober, S., Greenberg, P. L.
1983; 11 (5): 410-417
- **BIOLOGIC RATHER THAN MORPHOLOGIC MARKERS IN MYELOYDYSPLASTIC SYNDROMES** *BRITISH JOURNAL OF HAEMATOLOGY*
GREENBERG, P., BAGBY, G.
1983; 53 (3): 532-34
- **PURE WHITE-CELL APLASIA - ANTIBODY-MEDIATED AUTOIMMUNE INHIBITION OF GRANULOPOIESIS** *NEW ENGLAND JOURNAL OF MEDICINE*
Levitt, L. J., Ries, C. A., Greenberg, P. L.
1983; 308 (19): 1141-1146
- **RESPONSE OF AGRANULOCYTOSIS TO PROLONGED ANTI-THYMOCYTE GLOBULIN THERAPY** *JOURNAL OF PEDIATRICS*
CHUDWIN, D. S., Cowan, M. J., Greenberg, P. L., Wara, D. W., Ammann, A. J.
1983; 103 (2): 223-227
- **THE SMOLDERING MYELOID LEUKEMIC STATES - CLINICAL AND BIOLOGIC FEATURES** *BLOOD*
Greenberg, P. L.
1983; 61 (6): 1035-1044
- **INDUCTION OF HUMAN HEMATOPOIETIC STEM-CELL (CFU-GEMM) GROWTH BY FACTORS RELEASED FROM MITOGEN-STIMULATED SPLEEN-CELLS**
Fabian, I., Levitt, L., Greenberg, P.

ELSEVIER SCIENCE INC.1982: 167-167

- **ROLE OF INTRACELLULAR DEGRADATION OF EPIDERMAL GROWTH-FACTOR IN MITOGENESIS** *EXPERIMENTAL CELL RESEARCH*
Greenberg, P. L., ROZENGURT, E.
1982; 142 (1): 111-117
- **SPLENIC GRANULOCYTOPOIESIS AND PRODUCTION OF COLONY-STIMULATING ACTIVITY IN LYMPHOMA AND LEUKEMIA** *BLOOD*
Greenberg, P. L., STEED, S. M.
1981; 57 (1): 119-129
- **MONOCLONAL-ANTIBODY CHARACTERIZATION OF HUMAN MYELOID COLONY-FORMING CELLS (CFU-GM)**
GREENBERG, P., GROSSMAN, M., CHARRON, D., LEVY, R.
SLACK INC.1981: A88
- **STROMAL COLONY-STIMULATING ACTIVITY PRODUCTION AND MYELOID COLONY-FORMING CELLS IN HUMAN HEMATOPOIETIC AND NON-HEMATOPOIETIC BONE-MARROW** *BLOOD*
Schwartz, R. S., Greenberg, P. L.
1981; 57 (4): 771-780
- **CHARACTERIZATION OF ANTIGENIC DETERMINANTS ON HUMAN MYELOID COLONY-FORMING CELLS WITH MONOCLONAL-ANTIBODIES** *EXPERIMENTAL HEMATOLOGY*
Greenberg, P., Grossman, M., Charron, D., Levy, R.
1981; 9 (7): 781-787
- **THE CHRONIC IDIOPATHIC NEUTROPENIA SYNDROME - CORRELATION OF CLINICAL-FEATURES WITH INVITRO PARAMETERS OF GRANULOCYTOPOIESIS** *BLOOD*
Greenberg, P. L., MARA, B., Steed, S., Boxer, L.
1980; 55 (6): 915-921
- **MULTIVARIATE-ANALYSIS OF FACTORS PREDICTING OUTCOME OF TREATMENT FOR ADULTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)**
SCHWARTZ, R., HALPERN, J., GREENBERG, P.
AMER ASSOC CANCER RESEARCH.1980: 435
- **CLINICAL RELEVANCE OF INVITRO STUDY OF GRANULOCYTOPOIESIS** *SCANDINAVIAN JOURNAL OF HAEMATOLOGY*
Greenberg, P. L.
1980; 25 (5): 369-381
- **SUB-ACUTE MYELOID-LEUKEMIA - CLINICAL REVIEW** *AMERICAN JOURNAL OF MEDICINE*
Cohen, J. R., CREGER, W. P., Greenberg, P. L., Schrier, S. L.
1979; 66 (6): 959-966
- **Intramedullary influences on in vitro granulopoiesis in human acute myeloid leukemia.** *Haematology and blood transfusion*
Greenberg, P., MARA, B.
1979; 23: 199-204
- **PRELEUKEMIC SYNDROME - CORRELATION OF INVITRO PARAMETERS OF GRANULOPOIESIS WITH CLINICAL-FEATURES** *AMERICAN JOURNAL OF MEDICINE*
Greenberg, P. L., MARA, B.
1979; 66 (6): 951-958
- **MARROW ADHERENT CELL COLONY-STIMULATING ACTIVITY PRODUCTION IN ACUTE MYELOID-LEUKEMIA** *BLOOD*
Greenberg, P. L., MARA, B., Heller, P.
1978; 52 (2): 362-378
- **REMISSION OF ACUTE MYELOGENOUS LEUKEMIA COMPLICATING WALDENSTROM MACROGLOBULINEMIA** *WESTERN JOURNAL OF MEDICINE*
EFFRON, M. K., Rosenbaum, J., Greenberg, P. L.
1978; 129 (4): 337-339
- **REMISSION MAINTENANCE THERAPY IN ACUTE MYELOGENOUS LEUKEMIA** *WESTERN JOURNAL OF MEDICINE*

- Embury, S. H., Elias, L., Heller, P. H., HOOD, C. E., Greenberg, P. L., Schrier, S. L.
1977; 126 (4): 267-272
- **REMISSION MAINTENANCE THERAPY IN ACUTE MYELOGENOUS LEUKEMIA**
EMBURY, S. H., ELIAS, L., HELLER, P. H., HOOD, C. E., GREENBERG, P. L., SCHRIER, S. L.
SLACK INC.1977: A154
 - **DENSITY DISTRIBUTION PATTERNS OF MARROW COLONY-FORMING CELLS DURING REMISSION OF ACUTE MYELOGENOUS LEUKEMIA** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Heller, P., Greenberg, P.
1977; 59 (2): 313-316
 - **CYTOTOXIC EFFECTS OF INTERFERON INVITRO ON GRANULOCYTIC PROGENITOR CELLS** *CANCER RESEARCH*
Greenberg, P. L., MOSNY, S. A.
1977; 37 (6): 1794-1799
 - **DIVERGENT PATTERNS OF MARROW CELL-SUSPENSION CULTURE GROWTH IN MYELOID LEUKEMIAS - CORRELATION OF INVITRO FINDINGS WITH CLINICAL FEATURES** *BLOOD*
Elias, L., Greenberg, P.
1977; 50 (2): 263-274
 - **MYELOPROLIFERATIVE DISORDERS - CORRELATION BETWEEN CLINICAL EVOLUTION AND ALTERATIONS OF GRANULOPOIESIS** *AMERICAN JOURNAL OF MEDICINE*
Greenberg, P., MARA, B., Bax, I., BROSEL, R., Schrier, S.
1976; 61 (6): 878-891
 - **ALTERATION OF COLONY-STIMULATING FACTOR OUTPUT, ENDOTOXEMIA, AND GRANULOPOIESIS IN CYCLIC NEUTROPENIA** *AMERICAN JOURNAL OF HEMATOLOGY*
Greenberg, P. L., Bax, I., Levin, J., Andrews, T. M.
1976; 1 (4): 375-385
 - **CYTOTOXIC EFFECTS OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE AND 6-THIOGUANINE INVITRO ON GRANULOCYTIC PROGENITOR CELLS** *CANCER RESEARCH*
Greenberg, P. L., VANKERSEN, I., MOSNY, S.
1976; 36 (12): 4412-4417
 - **Cytotoxic effects of cytosine arabinoside and 6-thioguanine in vitro on granulocytic progenitor cells** *Cancer Res*
Greenberg, P. L., VanKersen, I., Mosny, S.
1976: 4412-4417
 - **HUMORAL AND CELLULAR ALTERATIONS IN CYCLIC NEUTROPENIA**
GREENBERG, P., BAX, LEVIN, J., ANDREWS, T.
SLACK INC.1975: A275
 - **GRANULOPOIESIS IN MYELOPROLIFERATIVE DISORDERS**
GREENBERG, P., MARA, B., BAX, BROSEL, R., SCHRIER, S.
W B SAUNDERS CO.1975: 1008
 - **ALTERATIONS OF GRANULOPOIESIS FOLLOWING CHEMOTHERAPY** *BLOOD*
GREENBER, P., Bax, I., MARA, B., Schrier, S.
1974; 44 (3): 375-383
 - **CLINICAL UTILITY OF INVITRO EVALUATION OF GRANULOPOIESIS** *ANNUAL REVIEW OF MEDICINE*
GREENBER, P. L., Schrier, S. L.
1974; 25: 269-278
 - **GRANULOPOIESIS IN NEUTROPENIC DISORDERS** *BLOOD*
GREENBER, P. L., Schrier, S. L.
1973; 41 (6): 753-769

- **The anemia of chronic disorders due to renal cell carcinoma: ferrokinetic and morphologic documentation of its surgical correction.** *The American journal of the medical sciences*
Greenberg, P. L., CREGER, W. P.
1971; 261 (5): 265-269
- **Granulopoiesis in acute myeloid leukemia and preleukemia** *New Engl J Med*
Greenberg PL, Nichols WC, Schrier SL
1971; 284: 1225-1232